

Oncology Centre Research Unit

TUMOR REGISTRY

Annual Report

2016





Oncology Centre Research Unit

TUMOR REGISTRY ANNUAL REPORT 2016

Annual Report Prepared by the Staff of the Tumor Registry
Research Unit, Oncology Centre
King Faisal Specialist Hospital and Research Centre
P.O. Box 3354, Riyadh 11211
Kingdom of Saudi Arabia
464-7272 ext. 80778
ORU@kfshrc.edu.sa

Tumor Registry Staff:

Salma Aljared, Tumor Registrar Mohamed Alammari, Tumor Registrar Abdul Rasim Thurakkal, Tumor Registrar Yara AlKurdi, Tumor Registrar Rehab Alsawi, Tumor Registrar

Doha Fatani, RPh, CCRP

Supervisor - Research Unit

August, 2020

TABLE OF CONTENTS

Int	troduction		5
I.	KFSH&RC	Tumor Registry	6
II.	Acknow	/ledgements	7
III.	KFSH&	RC Cancer Patient Population	8
		Distribution of Cases Accessioned By Year 975-2016)	8
	Table 1 -	Cases Seen at KFSH&RC (Male/Female and Pediatrics/ Adults) By 5-Year Period (1975-2016)	9
	•	Distribution of Cases By Nationality (1975-2016 and 016)	9
	Figure 3 -	Distribution of Cases By Region (1975-2016 and 2016)	10
	Trends in	Relative Frequency of Cancer at KFSH&RC	11
	Figure 4 -	Distribution of 20 Most Common Malignancies (1975-2016)	11
		Distribution of 5 Most Common Malignancies By Age at agnosis and SEER Summary Stage (1975-2016)	12
		Ten Most Common Malignancies By Age Group at Diagnosis 5-2016)	16
	Figure 6 -	Distribution of 10 Most Common Pediatric Malignancies (1975-2016)	17
		Distribution of 10 Most Common Pediatric Malignancies / Histology (1975-2016)	18
	Table 3 -	Cases Seen at KFSH&RC By Site and Year (1975-2016)	19
	Figure 8 -	Distribution of All Cases By Age at Diagnosis (2016)	22
	Figure 9 -	Distribution of Pediatric Cases By Age at Diagnosis (2016)	22
	Table 4 -	Cases Seen at KFSH&RC By Site, Sex, Class of Case and SEER Summary Stage (2016)	23
	Table 5 -	Analytic Cases Seen at KFSH&RC By Site and Age (2016)	24
	Table 6 -	Analytic Male Cases Seen at KFSH&RC By Site and Age (2016)	25
	Table 7 -	Analytic Female Cases Seen at KFSH&RC By Site and Age (2016)	26

Table 8 - Comparative Data – KFSH&RC vs SCR vs USA	27
Figure 10 - Distribution of 20 Most Common Malignancies (2016 Cases)	28
Figure 11 - Distribution of Pediatric Malignancies (2016 Cases)	29
Figure 12 - Distribution of 10 Most Common Pediatric Malignancies By Histology (2016 Cases)	29
Table 9 - Primary Site Table (2016)	30
Table 10 - Multiple primary site table (2016)	39
Stage of Disease at Diagnosis	44
Figure 13 - Distribution of Cases By Stage at Diagnosis (2016)	45
Table 12 - AJCC Clinical TNM Group Stage of Cases of Major Sites By Year (2011-2016)	46
IV. Saudi Cancer Registry (SCR) Annual Report 2016	48
V. Appendix	
Requests for Tumor Registry Data	49
VI.Glossary	50

INTRODUCTION

We are pleased to present 2016 Annual Tumor Registry Report for the King Faisal Specialist Hospital & Research Centre's Oncology Centre in Riyadh. The Cancer Registry maintains a complete database of information on all cancer cases diagnosed and/or treated at KFSH&RC. This database is an important patient care and quality assessment tool used by medical staff and administration for special studies, medical planning, resource allocation and utilization, education and research for comparing quality of care, monitoring patient care and continuous quality improvement. This report highlights the statistical overview of newly diagnosed cancer cases by site, gender, and AJCC Staging for both analytic and non-analytic cases. During 2016, the Tumor Registry abstracted 3000 new cancer cases. 2326 cases were analytic and 674 were non analytic; the highest incidence of cancer among males by site was leukemia, NHL and Brain carcinomas and among females was carcinomas of Breast, Thyroid, and leukemia. The Tumor Registry database includes over 86,993 cases and reports to the Saudi Cancer Registry (SCR).

Oncology Centre continues to provide comprehensive multidisciplinary care to our cancer patients. The Centre provides latest advances in radiation therapy, chemotherapy, hematopoietic stem cell transplantation, palliative and rehabilitation care to our patients. We also continue to be a center of excellence in cancer clinical research. Involvement in clinical trials allows our physicians and researchers to play an active role in advancing new cancer treatments and in providing the newest and most promising treatment options for our cancer patients. We have maintained our international cooperative group affiliations as the member of Southwest Oncology Group (SWOG), Radiation Therapy Oncology Group (RTOG/ NRG) and Canadian Blood & Marrow Transplantation Group (CBMTG). KFSH&RC has spearheaded the local and regional research consortiums as well, notably, Gulf Oncology Regional Group (GORG) and Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group. Research unit work load has mounted exponentially to keep pace with this exorbitant expansion of world class clinical research.

The Oncology Center is committed to serve as the pinnacle of excellence in the entire region. As we look to the future of cancer care in the Kingdom of Saudi Arabia, Oncology Centre will continue to deliver evidence based care centered upon the state-of-the art clinical and translational research.

We are extremely grateful to the dedicated staff of the Tumor Registry for their hard work and commitment throughout the year. Special thanks are due to the superb staff of Medical Records, a key component of the Registry's continued success. Hats off to our physicians, patient caregivers and support staff; it is their commitment and dedication that is the foundation for our success.

This report can be accessed online via Oncology Centre's website at http://www.kfshrc.edu.sa Your comments and suggestions are welcome to improve our future reports and can be sent to dfatani@kfshrc.edu.sa or f1515605@kfshrc.edu.sa

Doha Fatani, RPh, CCRP Supervisor, Research Unit Oncology Centre Ali Alshanqeeti, MD Director Oncology Centre

I. KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE TUMOR REGISTRY

The King Faisal Specialist Hospital and Research Centre (KFSH&RC) opened in June 1975 to provide specialized medical treatment to the people of Saudi Arabia and to promote the prevention of disease through research and education. It is a national and international tertiary care hospital for Oncology and the principal center for cancer therapy in Saudi Arabia.

The mission of the Tumor Registry, a hospital-wide data system, is to describe the burden of cancer in KFSH&RC by collecting complete and high quality cancer data and compiling timely statistics so that data-driven, evidence-based cancer prevention and control programs can be implemented to reduce cancer morbidity and mortality.

The Registry was established to meet one of the requirements for an Approved Cancer Program of the American College of Surgeons (ACoS). The database now includes 86,993 malignant cases seen at KFSH&RC from June 1975 through December 31, 2016.

The Registry is primarily staffed with tumor registrars who support the database in case ascertainment, abstracting, follow up and statistical analyses. The basic source document is the patient's medical record from which pertinent information is abstracted for use in the Registry. The electronic data system used was the Cansur 3.0 designed by the ACoS, for cases seen from 1975 to 2007. Starting with 2008 cases, the software being used is CNExT, developed by C/NET Solutions which is part of the U.S. Public Health Institute.

The data maintained in the Tumor Registry provides the statistics for the publication of the KFSH&RC Annual Report which summarizes the hospital's cancer experience. The data also supports a wide variety of reports at the request of physicians, researchers and ancillary personnel. These reports support patient management and outcome, basic and clinical research investigations, educational publications and presentations, and resource utilization. In 2016, the Tumor Registry supported myriad of data requests. It also identified and reported to the Saudi Cancer Registry 3000 new cases seen in 2016.

II. ACKNOWLEDGEMENTS

The cancer program is a combined effort of the extraordinary team of professionals at the King Faisal Specialist Hospital and Research Centre. It is not possible to enumerate all those involved in providing hope and healing to cancer patients and their families. The Tumor Registry staff greatly appreciates the tireless efforts of all the caring professionals from all disciplines for their dedication, commitment and collaboration to ensure highest standards in community outreach, clinical trials, staff education, patient care improvement, outcome analysis and tumor registry quality.

The clinical expertise and proficiency demonstrated by our team, coupled with an incredible dedication to patient care and service excellence, allows the Oncology Centre to achieve remarkable outcomes and to consistently exceed the needs and expectations of patients and their families.

The information in this report includes cancer incidence, site, and extent of disease at diagnosis, treatment, cancer trends, and outcomes to better understand the changing patterns of cancer.


The following departments have assisted throughout the year and without their support this report would not have been possible. The Tumor Registry staff takes pride in acknowledging these departments:

- Department of Pathology and Laboratory Medicine
- Medical Records Services
- Information Technology Affairs
- Department of Pediatric Hematology/Oncology
- Central Data Unit, Dept of Ped Hem/Onc
- Saudi Cancer Registry
- Home Health Care
- Oncology Centre

III. KFSH&RC CANCER PATIENT POPULATION

A total of 3000 cases were accessioned in 2016, with 1,366 males and 1,634 females or a male/female ratio of 0.8:1.

FIGURE 1
DISTRIBUTION OF CASES ACCESSIONED BY YEAR
1975-2016 (TOTAL CASES = 86,993)



From the opening of the hospital (mid 1975) until December 2016, 86,993 cancer cases were registered (43,215 males and 43,778 females) with a male/female ratio of 1.0:1.

There were 10,902 (12.5%) pediatric cases (0 to 14 years of age) and 76,091 (87.4%) adults (15 years old and above). In 2016, the proportions were 8.5% (256) for pediatrics and 91.4% (2,744) for adults.


TABLE 1
CASES SEEN AT KFSH&RC (MALE/FEMALE &PEDIATRICS/ADULTS) BY 5-YEAR PERIOD 1975-2016

	1975-1976*	1977-1981	1982-1986	1987-1991	1992-1996	1997-2001	2002 - 2006	2007-2011	2012-2016	TOTAL
MALE	280	2,980	4,150	4,969	5,562	6,427	6,529	5,819	6,499	43,215
FEMALE	135	1,945	3,358	4,341	5,347	6,753	7,199	6,952	7,748	43,778
TOTAL	415	4,925	7,508	9,310	10,909	13,180	13,728	12,771	14,247	86,993
M/F RATIO	2.1:1	1.5:1	1.2:1	1.1:1	1.0:1	1.0:1	0.9:1	0.8:1	0.8:1	1.0:1
PEDIATRICS	** 55	593	985	1164	1397	1892	1893	1566	1357	10,902
(%)	13.3%	12.0%	13.1%	12.5%	12.8%	14.4%	13.8%	12.3%	9.5%	12.5%
ADULTS	360	4,332	6,523	8,146	9,512	11,288	11,835	11,205	12,890	76,091
(%)	86.7%	88.0%	86.9%	87.5%	87.2%	85.6%	86.2%	87.7%	90.5%	87.5%
TOTAL	415	4,925	7,508	9,310	10,909	13,180	13,728	12,771	14,247	86,993


^{*} First two years of KFSH&RC partial operation.

FIGURE 2

DISTRIBUTION OF CASES BY NATIONALITY 1975 - 2016 (TOTAL CASES = 86,993)



2016 (TOTAL CASES = 3000)




Saudi nationals totaled 2,920 (97.3%) in 2016 and the non-Saudi, 80 (2.7%). During the period 1975 to 2016, the former accounted for 89.9% (78,227) while the latter, 10.1% (8,766).

^{**} Pediatrics = 0 to 14 years of age; Adults = 15 years and above.


Geographically, the referral pattern in 2016 was mainly from the Riyadh region with 43.2% of all cases, followed by the Asir Region with 10.6% then Eastern Province with 10.4% respectively. During the 41 years in review, 34.5% were referred from Riyadh, 13.9% from the Eastern Province and 10.3% from Mekkah.

These percentages reflect the KFSH&RC actual experience rather than adjusted to reflect the population of those regions.

FIGURE 3
DISTRIBUTION OF CASES BY REGION
(Based on Given Address at Time of Diagnosis)
1975 - 2016 (TOTAL CASES = 86,993)



2016 (TOTAL CASES = 3000)



TRENDS IN RELATIVE FREQUENCY OF CANCER AT KFSH&RC

The crude relative frequency is the proportion of a given cancer in relation to all cases in a clinical or pathological series. Although such frequencies are subject to many biases, historically many elevated frequencies have been confirmed when complete cancer registration was introduced.

Acceptance of cases to KFSH&RC is based on eligibility criteria, considering the nature of disease and availability of services.

Breast cancer led the list of total cancer cases seen from 1975 to 2016 with 13.9%, followed by leukemia (9.8%), Non-Hodgkin's lymphoma (8.3%), Thyroid (8.2%) and Brain (5.2%).

FIGURE 4

DISTRIBUTION OF 20 MOST COMMON MALIGNANCIES

1975-2016 (TOTAL CASES = 86,993)







FIGURE 5
DISTRIBUTION OF 5 MOST COMMON MALIGNANCIES
BY AGE AT DIAGNOSIS AND SEER SUMMARY STAGE
(1975 – 2016)

BREAST CANCER CASES






LEUKEMIA CASES



AGE IN YEARS

NON-HODGKIN'S LYMPHOMA CASES




Localized 479 (19%)


Distant 1,512 (58%)

Regional 594 (23%)


THYROID CANCER CASES







BRAIN CANCER CASES








TABLE 2


TEN MOST COMMON MALIGNANCIES BY AGE GROUP AT DIAGNOSIS 1975-2016

SITE	AGE GROUP	No	%	SITE	AGE GROUP	No	%
BREAST	00 - 14	2	0.0	HODGKIN	00 - 14	1,588	45.2
	15 - 39	3,090	29.2	DISEASE	15 - 39	1,313	37.4
	40 - 60	5,828	55.1		40 - 60	431	12.3
	>60	1,652	15.6		>60	178	5.1
SITE	AGE GROUP	No	%	SITE	AGE GROUP	No	%
LEUKEMIA	00 - 14	3,244	43.2	LIVER	00 - 14	114	3.8
	15 - 39	2,586	34.4		15 - 39	164	5.5
	40 - 60	1,171	15.6		40 - 60	1,089	36.4
	>60	503	6.7		>60	1,627	54.3
SITE	AGE GROUP	No	%	SITE	AGE GROUP	No	%
NON-HODGKIN'S	00 - 14	911	14.4	LUNG	00 - 14	14	0.5
LYMPHOMA	15 - 39	1,720	27.2		15 - 39	191	7.0
	40 - 60	1,852	29.3		40 - 60	1,030	37.8
	>60	1,840	29.1		>60	1,490	54.7
SITE	AGE GROUP	No	%	SITE	AGE GROUP	No	%
THYROID	00 - 14	123	2.0	NASOPHARYNX	00 - 14	106	3.9
	15 - 39	3,103	49.4		15 - 39	801	29.6
	40 - 60	2,111	33.6		40 - 60	1,246	46.0
	>60	940	15.0		>60	553	20.4
SITE	AGE GROUP	No	%	SITE	AGE GROUP	No	%
BRAIN	00 - 14	1,770	44.7	BLADDER	00 - 14	39	1.5
	15 - 39	1,088	27.5		15 - 39	252	9.8
	40 - 60	719	18.2		40 - 60	884	34.4
	>60	380	9.6		>60	1,395	54.3

Cancer among pediatrics (under the age of 15) accounted for 12.6% of all cases from 1975 to 2016. The five most common pediatric malignancies were Hemeretic (30%), brain (16.4%), Hodgkin's disease (9%), Non-Hodgkin's Lymphoma (8.4%), Bone (6.9%).

FIGURE 6


DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES
1975-2016 (TOTAL CASES = 10,902)



MALIGNANCIES

FIGURE 7

DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES BY HISTOLOGY 1975-2016 (TOTAL CASES = 10,902)



MALIGNANCIES

TABLE 3 CASES SEEN AT KFSH&RC BY SITE AND YEAR 1975-2016

1975-2016															
Site Group	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989
Oral Cavity	1	9	23	62	52	56	46	61	81	53	85	57	77	98	86
Nasopharynx	3	16	48	51	54	50	60	65	84	69	63	68	99	96	80
Esophagus	1	15	51	62	67	67	57	62	77	78	56	69	76	66	68
Stomach	2	15	32	35	50	37	49	51	64	60	49	64	61	47	52
Small intestine	0	0	4	0	2	2	2	1	0	5	3	5	1	1	6
Colon	1	10	10	12	12	16	20	19	16	24	13	24	35	35	30
Rectum & rectosigmoid	0	3	11	8	16	21	24	16	20	26	26	20	31	43	26
Anus,anal canal,anorectum	0	0	1	4	3	1	7	4	7	9	6	7	4	4	5
Liver	7	15	33	44	49	33	41	54	53	64	57	84	78	71	68
Gallbladder	0	2	3	4	2	2	4	6	4	4	6	7	14	9	5
Bile ducts	1	1	0	2	2	4	1	2	3	4	3	6	6	6	2
Pancreas	1	5	7	11	15	14	20	22	14	20	16	28	20	16	27
Retroperitoneum , Peritoneum	0	0	2	1	2	1	0	0	2	1	0	1	0	1	1
Other digestive	0	0	0	2	2	5	4	1	1	0	3	1	4	3	6
Nasal cavity,sinus,ear	1	3	9	7	5	7	9	10	10	5	7	5	16	14	7
Larynx	1	5	12	12	12	14	20	13	23	22	25	16	23	33	21
Lung/Bronchus	3	11	23	34	45	40	56	63	74	74	87	84	83	106	90
Pleura	0	0	1	0	0	0	0	0	1	1	0	1	0	1	2
Other respir & thoracic	0	0	0	1	1	1	3	1	1	0	4	0	6	1	1
Leukemia	7	28	40	87	90	83	121	125	117	127	121	159	185	157	155
Myeloma	1	5	6	11	9	11	8	13	13	12	19	13	29	22	33
Other hematopoietic	0	1	0	1	2	2	2	2	3	1	2	9	5	3	2
Bone	1	6	13	25	20	20	22	42	31	40	19	31	35	44	41
Soft tissue	1	16	29	29	31	23	29	40	32	35	38	47	48	49	59
Melanoma of skin	0	4	4	8	8	6	7	4	11	12	7	8	11	12	6
Kaposis sarcoma	0	1	1	0	6	4	2	2	5	4	5	9	5	9	5
Other skin cancers	2	13	26	32	41	35	48	54	51	52	62	60	43	43	53
Breast	3	24	53	46	57	65	101	111	111	153	131	127	174	194	137
Cervix uteri	0	10	18	18	25	18	26	25	33	33	41	55	51	50	33
Corpus uteri	1	1	2	5	6	4	8	8	11	14	10	10	16	21	21
Ovary	2	6	10	10	17	21	20	35	31	26	24	34	41	47	52
Vagina	0	0	5	2	0	1	2	0	2	2	3	1	2	1	2
Vulva	0	0	0	1	1	0	2	1	3	2	5	5	1	2	1
Other female genital	0	1	5	4	6	7	5	7	19	5	4	13	19	14	10
Prostate	0	7	5	4	5	10	11	18	28	19	19	17	22	27	27
Testis	0	3	9	8	10	11	15	11	7	12	14	14	17	17	9
Penis	0	1	1	0	1	0	2	2	3	4	0	0	0	2	2
Other male genital	0	0	0	0	2	0	1	0	1	0	3	0	3	0	2
Bladder	4	7	12	24	29	39	37	23	41	35	46	51	79	74	73
Kidney and renal pelvis	0	9	18	18	18	15	18	30	23	20	24	41	31	58	31
Ureter	0	0	0	0	0	0	0	0	0	1	1	0	3	1	1
Other urinary	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1
Eye	0	6	11	19	12	24	29	34	25	17	30	24	35	44	26
Brain, CNS	3	24	27	40	26	31	31	77	53	59	49	71	88	92	98
Thyroid	2	8	17	28	33	44	57	51	66	71	63	82	119	112	110
Other endocrine	1	1	3	3	2	9	10	8	14	12	17	10	11	13	2
Hodgkin's disease	13	19	40	41	36	42	47	42	54	50	49	45	65	57	76
Non-hodgkin's lymphoma	4	23	73	75	103	112	128	116	172	139	124	142	157	153	165
Unknown or ill-defined	3	11	23	24	20	27	34	30	33	26	25	25	37	32	42
TOTAL	70	345	721	915	1007	1035	1246	1362	1528	1503	1464	1651	1966	2001	1858
IUIAL	70	343	721	313	1007	1022	1240	1502	1328	1505	1404	1001	1900	2001	1000

TABLE 3 (cont 'd) CASES SEEN AT KFSH&RC BY SITE AND YEAR 1975-2016

Site Group	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Oral Cavity	81	87	85	72	77	99	82	94	71	92	102	75	74	107	78
Nasopharynx	84	76	80	85	78	84	111	107	124	118	98	141	86	111	116
Esophagus	72	66	69	47	50	50	52	51	62	34	52	37	42	43	37
Stomach	53	36	48	42	68	61	57	45	42	54	53	40	50	60	68
Small intestine	4	1	5	4	4	6	6	4	7	7	9	5	3	5	9
Colon	25	39	33	25	33	37	34	34	57	48	73	72	92	104	76
Rectum & rectosigmoid	31	35	48	46	52	48	54	62	59	94	75	77	106	99	113
Anus,anal canal,anorectum	8	6	7	12	10	5	6	6	7	4	7	7	8	14	5
Liver	55	66	76	82	103	102	103	96	84	89	85	91	73	70	60
Gallbladder	9	9	13	19	21	9	11	11	12	15	13	11	12	15	14
Bile ducts	4	2	7	2	7	3	9	7	10	9	8	9	10	7	4
Pancreas	12	13	27	21	22	25	21	24	34	18	38	26	31	30	34
Retroperitoneum , Peritoneum	1	0	2	1	0	1	0	0	1	2	2	1	1	1	4
Other digestive	2	1	2	4	0	3	0	0	0	0	0	2	0	2	4
Nasal cavity, sinus, ear	13	12	8	9	11	10	9	4	8	14	10	9	11	10	9
Larynx	26	34	27	31	35	37	36	31	30	35	32	33	26	47	41
Lung/Bronchus	74	85	79	85	89	87	84	88	106	108	91	80	91	86	94
Pleura	2	0	3	4	3	1	2	1	1	2	3	8	1	4	3
Other respir & thoracic	2	7	3	7	8	4	4	8	8	8	2	1	5	2	4
Leukemia	132	158	145	192	169	209	166	228	235	258	259	239	259	258	227
Myeloma	15	28	26	25	40	30	21	14	23	16	28	20	19	20	23
Other hematopoietic	2	0	1	0	2	2	2	1	3	4	9	11	10	9	2
Bone	37	40	52	54	56	56	56	63	71	63	75	83	74	62	68
Soft tissue	59	61	47	50	72	81	54	67	74	87	69	73	59	78	79
Melanoma of skin	5	9	15	9	7	7	9	5	5	6	5	5	6	5	8
Kaposis sarcoma	4	5	14	2	3	6	11	6	8	8	4	7	9	9	6
Other skin cancers	41	47	47	51	61	44	57	52	35	58	52	62	38	52	49
Breast	168	169	188	251	241	232	281	292	336	341	383	362	377	409	431
Cervix uteri	44	35	52	50	52	49	48	46	62	57	42	68	53	55	47
Corpus uteri	18	13	27	20	26	22	19	26	29	33	33	35	47	59	62
Ovary	46	36	44	55	50	55	56	60	63	53	53	51	44	55	51
Vagina	3	3	2	0	5	5	2	2	1	2	1	0	1	1	2
Vulva	4	5	1	4	5	5	2	1	0	1	2	3	2	2	3
Other female genital	9	13	12	12	19	7	11	8	6	6	5	5	10	13	12
Prostate	24	16	41	27	45	37	49	43	44	63	47	49	49	59	59
Testis	14	14	21	25	21	14	14	17	16	19	20	18	28	19	20
Penis	5	2	0	1	3	0	1	3	0	0	2	0	1	1	0
Other male genital	0	0	0	1	1	0	0	0	1	0	0	1	2	1	2
Bladder	60	44	65	88	72	60	56	65	85	91	80	81	71	93	102
Kidney and renal pelvis	35	33	52	51	65	48	47	49	58	70	57	72	64	55	70
Ureter	0	1	1	1	1	1	1	0	3	1	2	3	2	2	1
Other urinary	0	1	1	0	0	0	0	0	0	2	1	0	0	0	1
Eye	30	9	15	39	27	15	22	30	17	24	26	17	16	20	18
Brain,CNS	81	84	112	88	116	128	129	133	162	145	149	151	143	161	167
Thyroid	94	110	141	135	158	134	162	161	192	210	186	189	169	215	214
Other endocrine	7	10	14	15	15	14	14	20	12	15	23	14	18	38	27
Hodgkin's disease	56	57	75	73	78	88	76	76	98	116	131	121	121	132	144
Non-hodgkin's lymphoma	154	123	150	154	160	158	157	193	208	207	204	175	186	206	218
Unknown or ill-defined	39	40	51	42	62	36	41	35	50	50	45	49	53	45	49
TOTAL	1744	1741	2034	2113	2303	2215	2245	2369	2620	2757	2746	2689	2653	2951	2935
IOIAL	1/44	1/41	2034	2113	2303	2213	2243	2303	2020	2/3/	2/40	2003	2000	2331	2333

TABLE 3 (cont 'd) CASES SEEN AT KFSH&RC BY SITE AND YEAR 1975-2016

1975-2016													
Site Group	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	TOTAL
Oral Cavity	106	83	109	94	92	61	90	76	82	89	90	96	3191
Nasopharynx	97	91	83	88	67	85	86	69	80	68	67	76	3362
Esophagus	41	36	30	31	31	28	31	30	21	30	25	26	1996
Stomach	57	59	48	49	64	59	56	60	62	76	56	43	2134
Small intestine	6	4	5	5	7	4	6	8	11	20	6	9	202
Colon	80	95	88	83	96	84	103	101	119	131	155	139	2333
Rectum & rectosigmoid	112	93	92	82	92	83	93	99	92	100	115	115	2458
Anus,anal canal,anorectum	5	3	5	5	1	4	2	3	5	7	4	10	228
Liver	37	68	50	72	89	97	112	103	103	88	91	98	2994
Gallbladder	8	8	11	10	6	9	11	5	11	22	17	12	396
Bile ducts	8	6	11	7	12	13	8	10	9	12	17	16	270
Pancreas	27	41	26	32	40	36	31	46	61	61	50	50	1113
Retroperitoneum, Peritoneum	2	2	2	3	1	3	2	5	8	5	5	15	82
Other digestive	2	1	1	4	1	2	0	0	0	0	3	1	67
Na sal cavity, sinus, ear	13	11	12	8	8	5	4	7	4	4	11	9	358
Larynx	36	26	32	31	26	10	17	19	21	18	23	20	1032
Lung/Bronchus	84	64	60	63	61	63	73	72	81	91	63	81	3056
Pleura	3	1	3	2	4	1	0	3	3	0	4	1	70
Other respir & thoracic	3	3	1	4	7	7	6	5	5	2	3	6	145
Leukemia	205	225	205	227	219	233	205	288	259	242	226	234	7504
Myeloma	23	22	31	18	39	36	28	15	30	26	25	28	874
Other hematopoietic	8	11	7	22	14	27	23	3	1	7	21	41	278
Bone	69	66	52	74	59	55	62	54	49	64	39	50	1993
Soft tissue	70	54	83	56	54	72	67	73	72	61	64	54	2296
Melanoma of skin	5	8	5	8	6	7	5	7	4	4	8	6	287
Ka posis sarcoma	8	9	7	7	7	10	5	3	5	12	10	3	246
Other skin cancers	56	66	30	41	41	39	42	36	49	44	47	49	1901
Breast	378	326	349	357	338	375	411	373	431	483	397	406	10572
Cervix uteri	46	38	39	43	46	32	34	42	35	43	33	29	1656
Corpus uteri	48	59	68	64	74	56	73	72	63	93	91	90	1458
Ovary	48	55	44	54	49	69	51	47	49	50	51	56	1771
Vagina	1	0	0	0	2	0	2	1	0	1	5	2	67
Vulva	2	0	2	4	3	2	5	4	2	2	1	2	93
Other female genital	12	15	8	6	10	3	4	2	4	4	5	2	342
Prostate	75	46	39	60	45	47	37	37	45	60	64	59	1485
Testis	17	11	15	28	26	27	23	14	27	33	37	26	721
Penis	2	0	0	0	1	0	0	2	0	0	0	1	43
Other male genital	. 1	2	0	0	0	0	1	1	0	0	2	3	31
Bladder	88	66	69	65	66	82	66	61	78	75	75	93	2571
Kidney and renal pelvis	61	67	67	85	86	85	86	82	78	90	92	98	2157
Ureter	. 2	0	1	0	2	2	2	0	0	0	1	1	38
Other urinary	2	0	0	0	0	0	0	3	1	1	2	1	19
Eye Proin CNS	15	20	11	19	17	24	32	27	22	22	20	18	908
Brain,CNS	128	126	91	94	85	101	107	100	88	93	116	173	4020
Thyroid Other endeering	216	205	229	254	225	212	245	247	245	280	291	291	6273
Other endocrine	26	23	17	30	22	28	17	24	14	19	22	22	636
Hodgkin's disease	130	101	118	118	122	104	96	117	107	142	113	121	3507
Non-hodgkin's lymphoma	181	167	178	172	148	163	139	154	160	156	197	169	6323
Unknown or ill-defined	32	28	19	25	31	31	24	22	39	30	27	49	1436
TOTAL	2682	2511	2453	2604	2542	2576	2623	2632	2735	2961	2887	3000	86993

The largest number of cases in 2016 was noted in the 5th and 6th decades of life in males and in the 4th and 5th in females. The mean age was 46, the median was 48 and the mode was at 52. Pediatric malignancies were most common among children at one year of age and at less than one year of age.

FIGURE 8
DISTRIBUTION OF ALL CASES BY AGE AT DIAGNOSIS
2016 (TOTAL CASES = 3000)





FIGURE 9
DISTRIBUTION OF PEDIATRIC CASES BY AGE AT DIAGNOSIS
2016 (TOTAL CASES = 256)



Of the 3,000 cases in 2016, 2,580 (86%) were analytic (defined as cases which were first diagnosed and/or received all or part of their first course of treatment at KFSH&RC). The remaining 420 cases (14%) were non-analytic (defined as cases diagnosed elsewhere and received all of their first course of treatment elsewhere). Out of the 2,580 analytic cases, pediatric cases totaled 256, with 147 males and 109 females.

See Table 4 for the distribution of cases by site, sex, class of case, and stage at diagnosis.

(TABLE 4) CASES SEEN AT KFSH&RC BY SITE, SEX, CLASS OF CASE, AND SUMMARY STAGE 2016

	Total	Cla	ss	Se	ex			Sta	ge		
SITE GROUPS		Analytic		М	F	In Situ	Local	REGIONAL	Distant	Reg NOS	UNSTAGEABLE
Oral Cavity	95	80	15	54	41	0	16	50	5	1	8
Nasopharynx	93 77	63	14	57	20	0	8	44	10	0	1
Esophagus	26	21	5	19	7	0	4	13	4	0	0
Stomach	43	38	5	31	12	0	8	10	11	1	8
Small Intestine	9	9	0	6	3	0	0	6	2	0	1
Colon	139	116	23	70	69	3	15	45	47	3	3
Rectum &Rectosigmoid	115	97	18	62	53	2	14	41	34	3	3
Anus, Canal, Anorectum	10	10	0	8	2	0	1	7	2	0	0
Liver	98	89	9	62	36	0	40	12	17	0	20
Gallbladder	12	9	3	6	6	1	1	4	3	0	0
Bile Duct	16	15	1	8	8	0	4	6	5	0	0
Pancreas	50	47	3	26	24	0	6	9	27	0	5
Retroperitoneum	5	3	2	4	1	0	2	0	1	0	0
Peritoneum,Omentum,Mesent	9	7	2	3	6	0	0	0	6	0	1
Other Digestive Organs	1	0	1	1	0	0	0	0	0	0	0
Nose, Nasal, Middle Ear	9	8	1	5	4	0	1	5	0	1	1
Larynx	20	17	3	18	2	1	10	5	0	0	1
Lung and Bronchus	79	71	8	50	29	0	11	17	39	0	4
Pleura	1	1	0	1	0	0	1	0	0	0	0
Other Respiratory & Thoracic	7	6	1	6	1	0	0	3	2	0	1
Bones & Joints	50	48	2	32	18	0	19	10	11	0	8
Soft Tissue	54	47	7	29	25	0	20	12	3	0	12
Melanoma - Skin Other Skin Cancers	6 18	6 17	0	2 12	4 6	0	2 6	1 2	3 5	0	0
Other Skin Cancers Breast	405	17 347	1 58	3	402	18	106	2 161	5 50	0 1	4 11
Cervix Uteri	29	28	36 1	0	29	8	4	11	4	0	1
Corpus Uteri	90	77	13	0	90	1	44	14	15	0	3
Ovary	55	43	12	0	55	0	9	3	22	1	8
Vagina	2	2	0	0	2	1	0	0	1	0	0
Vulva	2	2	0	0	2	0	1	1	0	0	0
Other Female Genital	2	2	0	0	2	0	0	0	1	0	1
Prostate	59	51	8	59	0	1	18	12	17	1	2
Testis	26	20	6	26	0	0	12	4	3	0	1
Penis	1	1	0	1	0	0	0	1	0	0	0
Other Male Genital	3	3	0	3	0	0	1	1	1	0	0
Bladder	93	75	18	78	15	24	32	11	4	0	4
Kidney, Renal Pelvis	98	87	11	64	34	0	48	22	11	0	6
Ureter	1	1	0	1	0	0	0	0	1	0	0
Other Urinary Organs	1	1	0	1	0	0	1	0	0	0	0
Eye & Orbit	18	16	2	11	7	0	4	6	0	1	5
Brain ,CNS	173	155	18	85	88	3	65	3	1	57	26
Thyroid	291	253	38	72	219	4	116	87	8	1	37
Other Endocrine	22	20	2	13	9	1	4	4	5	0	6
Hodgkin Lymphoma	121	93	28	66	55 72	0	18	1	43	23	8
Non-Hodgkin Lymphoma Multiple Myeloma	175 28	149 24	26 4	103 18	72 10	0 0	27 2	9 0	72 21	20 0	21 1
Leukemia	28	24 191	32	122	101	0	0	1	188	0	2
Mesothelioma	3	191	2	2	101	0	0	0	1	0	0
Kaposi Sarcoma	3	3	0	1	2	0	1	1	0	0	1
Miscellaneous	96	82	14	50	46	0	7	4	56	0	15
Unknown or ill-Defined	31	28	3	15	16	2	11	9	2	0	4
Total	3000	2580	420	1366	1634	70	720	668	764	114	244

(TABLE 5) ANALYTIC CASES SEEN AT KFSH&RC BY SITE AND AGE 2016

Site Group	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	TOTAL
Oral Cavity	0	0	1	1	4	2	6	2	6	5	10	10	8	10	12	9	5	4	95
Nasopharynx	0	0	2	0	2	2	9	6	6	14	11	10	8	0	4	2	0	1	77
Esophagus	0	0	0	0	0	1	1	0	1	1	5	2	4	1	5	1	1	3	26
Stomach	0	0	0	1	1	2	1	2	3	2	4	5	8	3	3	5	3	0	43
Small intestine	0	0	0	0	0	0	0	0	0	1	2	0	1	2	1	2	0	0	9
Colon	0	0	0	1	0	3	1	10	6	20	24	18	23	10	7	10	5	1	139
Rectum & rectosigmoid	0	0	0	0	0	2	5	8	9	14	14	14	13	14	8	9	3	2	115
Anus,anal canal,anorectum	0	0	0	0	0	1	0	0	2	1	1	0	1	2	1	1	0	0	10
Liver	1	2	0	1	1	1	1	2	6	2	9	18	17	10	13	5	8	1	98
Gallbladder	0	0	0	1	0	0	0	0	1	2	2	1	1	2	2	0	0	0	12
Bile ducts	0	0	0	0	1	0	0	1	1	1	1	3	3	0	3	1	1	0	16
Pancreas	0	0	0	0	0	2	1	1	5	4	5	5	10	5	8	2	2	0	50
Retroperitoneum,Peritoneum	0	0	0	0	1	1	1	0	0	2	0	4	2	1	1	1	0	0	14
Other digestive	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Nasal cavity, sinus, ear	1	0	0	2	0	0	0	0	3	0	0	0	1	0	2	0	0	0	9
Larynx	0	0	0	0	0	1	0	0	1	2	2	7	1	2	2	0	1	1	20
Lung , Bronchus	1	0	0	0	0	6	3	5	4	2	13	10	8	12	11	4	2	0	81
Pleura	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Other respir & thoracic	0	0	0	1	1	2	0	0	0	0	3	0	0	0	0	0	0	0	7
Leukemia	40	18	20	17	10	10	20	13	9	24	12	8	6	9	2	2	3	0	223
Myeloma	0	0	0	0	10	0	1	2	2	2	3	7	4	2	1	1	2	0	28
Other hematopoietic	3	1	5	3	1	5	3	4	4	2	2	4	2	2	0	0	0	0	41
Bone	2	9	8	6	7	7	2	3	0	1	1	0	1	0	2	1	0	0	50
Soft tissue	2	1	6	4	4	6	6		4	4	3		3	2	2	0	0	0	54
Melanoma of skin	0	0	0	1	0	0	0	6 2	0	0	0	1 0	0	1	1	1	0	0	6
Kaposis sarcoma	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	0	0	0	4
Other skin ca			0	2	0	5	7	2	3	2	2	1	2	4	6	5	3	2	49
Breast	1 0	2 0	0	3	2	10	21	34	5 67	75	79	42	29			6	5	4	405
Cervix Uteri	0	0	0	0	2	0	0	5		1	79	2		16 3	12	2		0	29
				0				2	4		6	2 16	1 22		1		1		90
Corpus uteri Uterus nos	0	0	0	0	0	3 0	1 1	2	10 1	7 1	2	10	1	8 1	6 0	5 0	2 0	2 0	10
	0	0		5		5	6		5	7	3	8	2	5		1		0	56
Ovary			1	0	3			1							3		1	0	2
Vagina Vulva	0	0	0	0	0 1	0	0	1	0	0	1 0	0	0	0	0	0	0	0	2
	0	0	0	0	0	0	0	0	0	2	0	0	0			1 0		0	2
Other female genital	0	0	0	0	0	0	0	0	0	2	3	7	13	0 10	0	9	0	2	59
Prostate Testis	1		0	6	3	5	8	0		1		0	0	0	10 0		3 0	0	26
Penis		0	0						1		1					0			1
	0	0	0	0	0	0	0	0	0	0	1 0	0	0	0 1	0	0	0	0	3
Other male genital	0			1	0	0	0	0	0	0		0	1		0	0		0	93
Bladder	3	0	0 1	0 0	0	0	2 8	2 2	3 8	15	9 12	11 12	12 15	12	8 4	11 3	3 1	2	93 98
Kidney and renal pelvis	9	3 0			0	1				9				9				1	90 1
Ureter	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	-
Other urinary	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
Eye	15	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	18
Brain,CNS	16	14	7	11	10	13	15	12	16	16	7	10	7	7	8	4	0	0	173
Thyroid	0	3	3	6	19	29	38	34	28	35	28	27	17	9	6	7	2	0	291
Other endocrine	6	1	1	0	2	0	0	2	1	1	3	1	2	1	0	1	0	0	22
Hodgkin's disease	2	7	10	16	21	20	18	9	3	4	2	3	1	1	1	1	2	0	121
Non-hodgkin's lymphoma	4	5	7	7	15	12	10	12	13	11	14	23	9	11	7	10	2	3	175
Unknown or ill-defined	5	4	0	6	5	1	3	1	1	4	1	4	5	4	3	1	1	0	44
TOTAL	112	71	72	102	120	158	199	188	237	300	308	295	265	194	168	124	63	29	3000

(TABLE 6) ANALYTIC MALE CASES SEEN AT KFSH&RC BY SITE AND AGE 2016

Site Group	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	TOTAL
Oral cavity	0	0	1	0	2	1	4	2	2	1	7	6	3	5	7	6	4	2	53
Nasopharynx	0	0	3	0	1	1	7	4	5	12	8	7	6	0	2	1	0	1	58
Esophagus	0	0	0	0	0	0	0	0	1	1	4	2	2	1	4	1	1	2	19
Stomach	0	0	0	1	1	1	1	1	2	2	2	4	4	3	3	3	3	0	31
Small intestine	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0	2	0	0	6
Colon	0	0	0	0	0	2	0	3	4	9	9	14	11	6	2	5	4	1	70
Rectum & rectosigmoid	0	0	0	0	0	0	3	4	7	7	8	7	7	6	6	7	0	0	62
Anus,anal canal,anorectum	0	0	0	0	0	1	0	0	2	0	1	0	1	1	1	1	0	0	8
Liver	1	0	0	0	0	1	1	1	3	0	9	8	8	8	8	4	8	2	62
Gallbladder	0	0	0	1	0	0	0	0	1	0	0	0	0	2	2	0	0	0	6
Bile ducts	0	0	0	0	0	0	0	1	1	1	1	1	1	0	1	0	1	0	8
Pancreas	0	0	0	0	0	2	1	0	1	3	4	1	5	2	6	1	0	0	26
Retroperitoneum/peritoneum	0	0	0	0	1	0	1	0	0	2	0	2	1	0	0	1	0	0	8
Other digestive	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Nasal cavity, sinus, ear	0	0	0	0	0	0	0	0	3	0	0	0	0	0	2	0	0	0	5
Larynx	0	0	0	0	0	1	0	0	1	2	1	6	1	2	2	0	1	1	18
Lung / bronchus	0	0	0	0	0	3	2	2	1	1	8	7	4	8	9	4	1	0	50
Pleura	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Other respir & thoracic	0	0	0	0	2	2	0	0	0	0	2	0	0	0	0	0	0	0	6
leukemia	21	10	9	13	4	7	12	9	4	13	5	4	4	2	2	1	2	0	122
Myeloma	0	0	0	0	1	0	1	0	2	2	1	4	3	2	0	1	1	0	18
Other hematopoietic	2	0	2	1	0	3	2	2	3	1	1	1	1	0	0	0	0	0	19
Bone	1	5	4	4	5	6	1	1	0	1	1	0	0	0	2	1	0	0	32
Soft tissue	0	0	4	2	3	3	3	3	3	1	1	1	2	2	1	0	0	0	29
Melanoma of skin	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	2
Kaposis sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
Other skin ca	1	1	0	0	0	4	2	1	2	1	0	1	1	2	3	4	3	1	27
Breast	0	0	0	0	0	0	0	1	0	1	1	1	0	0	0	0	0	0	4
Prostate	0	0	0	0	0	0	0	0	0	3	3	6	13	10	10	9	3	2	59
Testis	1	0	0	6	3	5	8	0	1	1	1	0	0	0	0	0	0	0	26
Penis	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1
Other male genital	0	0	0	1	0	0	0	0	0	0	0	0	1	1	0	0	0	0	3
Bladder	3	0	0	0	0	0	1	2	3	10	6	9	12	12	6	9	3	1	77
Kidney and renal pelvis	6	1	1	0	0	0	4	2	6	7	7	6	11	8	2	1	1	1	64
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
Other urinary	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
Eye	8	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	11
Brain, CNS	11	10	5	5	5	6	7	4	6	6	4	5	3	2	4	2	0	0	85
Thyroid	0	1	1	1	3	5	9	10	3	9	8	6	5	3	2	4	2	0	72
Other endocrine	3	1	1	0	1	0	0	1	1	0	2	1	1	1	0	0	0	0	13
Hodgkin's disease	1	6	6	8	11	8	13	2	1	3	2	2	1	1	0	0	1	0	66
Non-hodgkin's lymphoma	2	3	6	5	8	6	7	6	5	7	8	13	3	5	7	7	2	3	103
Unknown or ill-defined	3	2	0	4	3	1	2	1	0	3	0	2	4	3	3	0	1	0	32
TOTAL	64	41	43	52	57	69	92	64	74	111	117	127	121	101	98	75	43	17	1366

(TABLE 7) ANALYTIC FEMALE CASES SEEN AT KFSH&RC BY SITE AND AGE 2016

2016																			
Site Group	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	TOTAL
Oral Cavity	0	0	0	1	2	1	2	0	3	4	3	4	5	5	5	3	1	2	41
Nasopharynx	0	0	0	0	1	1	1	1	1	1	3	2	2	0	2	0	0	0	15
Hypopharynx	0	0	0	0	0	0	1	1	0	1	0	1	0	0	0	1	0	0	5
Esophagus	0	0	0	0	0	1	1	0	0	0	1	0	2	0	1	0	0	1	7
Stomach	0	0	0	0	0	1	0	1	1	0	2	1	4	0	0	2	0	0	12
Small intestine	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	3
Colon	0	0	0	1	0	1	1	7	2	11	15	4	12	4	5	5	1	0	69
Rectum & rectosigmoid	0	0	0	0	0	2	2	4	2	7	6	7	6	8	2	2	3	2	53
Anus, anal canal, anorectum	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	2
Liver	0	2	0	1	1	0	0	1	3	2	0	8	9	2	5	1	0	1	36
Gallbladder	0	0	0	0	0	0	0	0	0	2	2	1	1	0	0	0	0	0	6
Bile ducts	0	0	0	0	1	0	0	0	0	0	0	2	2	0	2	1	0	0	8
Pancreas	0	0	0	0	0	0	0	1	4	1	1	4	4	3	2	1	2	1	24
Retroperitoneum, Peritoneum	0	0	0	0	0	1	0	0	0	0	0	2	1	1	1	0	1	0	7
Nasal cavity, sinus, ear	1	0	0	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	4
Larynx	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	2
Lung/bronchus	1	0	0	0	0	2	1	2	3	1	5	3	4	4	2	0	1	0	29
Other respir & thoracic	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Leukemia	20	8	11	3	4	5	14	4	5	11	7	4	2	7	0	1	1	0	107
Myeloma	0	0	0	0	0	0	0	2	0	0	2	3	1	0	1	0	1	0	10
Other hematopoietic	1	1	3	2	1	2	1	2	1	1	1	3	1	2	0	0	0	0	22
Bone	1	4	4	2	2	1	1	2	0	0	0	0	1	0	0	0	0	0	18
Soft tissue	2	1	2	2	1	3	3	3	1	3	2	0	1	0	1	0	0	0	25
Melanoma of skin	0	0	0	1	0	0	0	1	0	0	0	0	0	1	0	1	0	0	4
Kaposis sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	2
Other skin ca	0	1	0	2	0	1	5	1	1	1	2	0	1	2	3	1	0	0	21
Breast	0	0	0	3	2	10	21	33	67	74	78	41	30	16	13	6	5	4	403
Cervix Uteri	0	0	0	0	2	0	0	5	4	1	7	2	1	3	1	2	1	0	29
Corpus uteri	0	0	0	0	0	3	1	2	5	7	6	16	17	8	6	5	2	2	80
Uterus nos	0	0	0	0	0	0	1	2	1	1	2	1	1	1	0	0	0	0	10
Ovary	0	0	1	5	3	5	6	1	5	7	3	8	2	5	3	1	1	0	56
Vagina	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	2
Vulva	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	2
Other female genital	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	2
Bladder	0	0	0	0	0	0	1	0	0	4	3	2	0	0	2	2	0	1	15
Kidney and renal pelvis	3	2	0	0	0	1	4	0	2	2	5	6	4	1	2	2	0	0	34
Eye	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
Brain, CNS	5	4	2	6	5	7	8	8	10	10	3	5	4	5	4	2	0	0	88
Thyroid	0	2	2	5	16	24	29	24	25	26	20	21	12	6	4	3	0	0	219
Other endocrine	3	0	0	0	10	0	0	24 1	0	1	1	0	12	0	0	3 1	0	0	9
Hodgkin's disease	3 1	1	4	8	10	12	5	7	2	1	0	1	0	0	1	1	1	0	55
-	2	2	1	o 1	6	5	2	6	8	4		10	6	6		3		0	55 70
Non-hodgkin's lymphoma Unknown or ill-defined		2									6				1		1	-	
Unknown of III-defined	2	2	0	2	2	0	1	0	1	1	1	2	3	1	1	1	0	0	20
TOTAL	49	30	30	48	61	89	112	123	157	188	190	165	141	93	73	49	22	14	1634

TRENDS IN RELATIVE FREQUENCY OF CANCER AT KFSH&RC (cont'd)

The crude relative frequencies of primary cancers seen at KFSH&RC are very different from the Western world. Common tumors of the West (lung, colon, and prostate) are much less frequent here while leukemia, lymphoma and thyroid cancers are more common. The following 2016 analytic cases, which show a quite similar pattern with the data from the Saudi Cancer Registry (SCR), exhibit significant differences in trends from those of the U.S.A when compared to the data published in Cancer Facts & Figures - 2016, by the American Cancer Society:

TABLE 8

COMPARATIVE DATA - KFSH&RC vs SCR vs USA

(% to TOTAL CANCER CASES)

SITE	KFSH&RC 2016 Analytics	SCR 2016 Saudis	USA 2016 Estimates
BREAST	15.2%	17.3%	14.7%
THYROID	10.9%	8.2%	3.8%
LEUKEMIA	8.8%	4.6%	3.5%
COLON, RECTUM	7.5%	12.6%	7.9%
NON-HODGKIN'S LYMPHOMA	6.3%	6.4%	4.3%
LIVER	3.7%	3.2%	2.3%
HODGKIN'S LYMPHOMA	4.5%	3.8%	0.5%
ORAL CAVITY	1.4%	2.0%	2.8%
BRAIN	6.0%	3.7%	1.4%
KIDNEY & RENAL PELVIS	3.7%	3.4%	3.7%
LUNG/BRONCHUS	2.9%	3.4%	13.3%

Breast - The most common malignancy seen at KFSH&RC is breast cancer, comprising 15.2% of all cases, as compared to 14.7% of all neoplasms diagnosed in the U.S.A. It affects mostly women under the age of 50, while in the U.S.A., those more than 50 years of age are most frequently affected. As in the Western countries, it is the number one cancer among women.

Thyroid – 10.9% of all malignancies in KFSH&RC are thyroid cancer, much higher than in the West. It represents 13.4% of female malignant neoplasms, second to breast cancer. The male/female ratio is 0.3:1. Thyroid cancer accounts for only 3.8% of all cases in the U.S.A., and 5.8% of female malignancies.

Leukemia - The most striking feature is the high crude relative frequency of leukemia cases, constituting 8.8% of all cases seen at KFSH&RC, as compared to 3.5% of all neoplasms diagnosed in the U.S.A. The male/female ratio is 1.1:1. It is the most common malignancy seen in males and third most common malignancy in females. It is also the most common malignancy among pediatric cases.

Colon, Rectum - Less common than in the West, this disease represents only 7.5% of all cancer cases. In the U.S.A., it constitutes 7.9% of newly diagnosed cancer cases. Dietary factors, particularly lower animal fat intake, may play a role.

Non-Hodgkin's Lymphoma - Cases of non-Hodgkin's lymphoma account for 6.3% of all cases. In the U.S.A., NHL accounts for only 4.3% of all cancers.

Liver – The relative frequency of Liver cases at KFSH&RC is 3.7% as compared to the West recorded as 2.3%.

Hodgkin's Lymphoma - The incidence of Hodgkin's lymphoma is comparatively more frequent at KFSH&RC than in Western countries. In the U.S.A., it constitutes 0.5% of all cancers, compared to 4.5% at KFSH&RC.

Oral cavity – A crude relative frequency rate was also noted in cancer of Oral Cavity. In Western countries, oral cancer accounts 2.8% of all cancers, whereas at KFSH&RC represents 1.4% of the cases.

Brain, CNS - Primary malignant neoplasms of the brain and CNS account for 6% of all malignancies. This is much higher than in the U.S.A., with only 1.4% of all cases.

Kidney & renal pelvis – frequency of Kidney & Renal Pelvis malignancies in Western Countries is as same as in KFSH&RC, which is 3.7%.

Lung - Frequency of lung cancer at KFSH&RC is much lower than in Western countries, most likely reflecting the significantly lower levels of smoking and industrial pollution. In the U.S.A., primary lung cancer represents 13.3% of all cancer cases. At KFSH&RC, 2.9% of all cancer diagnoses are lung cancers.

FIGURE 10 DISTRIBUTION OF 20 MOST COMMON MALIGNANCIES 2016 ANALYTIC CASES (TOTAL CASES = 2,580)

MALE

LEUKEMIA 127 (9.30%)

NHL 99 (7.25%)

BRAIN 83 (6.06%)

THYROID 72 (5.27%)

COLON 70 (5.12 %)

HODGKIN DISEASE 66 (4.83%)

KIDNEY, RENAL PELVIS 64 (4.69%)

RECTUM 62 (4.54%)

LIVER 62 (4.54%)

PROSTATE 59 (4.32%)

NASOPHARYNX 55 (4.03%)

LUNG / BRONCHUS 47 (3.44%)

ORAL CAVITY 34 (2.49%)

BONE 32 (2.34%)


STOMACH 31 (2.27%)

SOFT TISSUE 29 (2.12%)

OTHER SKIN CA 27 (1.99%)

PANCREAS 26 (1.90%)

TESTIS 26 (1.90%)



FEMALE

. _....

BREAST 402 (24.60%)

THYROID 219 (13.40%)

LEUKEMIA 107 (6.55%)

CORPUS UTERI 80 (4.90%)

BRAIN 76 (4.65%)

NHL 70 (4.28%)

COLON 69 (4.22 %)

OVARY 56 (3.43%)

HODGKIN DISEASE 55 (3.37%)

RECTUM 53 (3.24%)

LIVER 36 (2.20%)

KIDNEY, RENAL PELVIS 34 (2.09%)

ORAL CAVITY 31 (1.90%)

LUNG, BRONCHUS 29 (1.77%)

SOFT TISSUE 25 (1.53%)

PANCREAS 24 (1.47%)

OTHER SKIN CA 22 (1.35%)

CERVIX UTERI 22 (1.35%)

BONE 18 (1.10%)

BLADDER 15 (0.92%)

FIGURE 11 DISTRIBUTION OF MOST COMMON PEDIATRIC MALIGNANCIES 2016 ANALYTIC CASES (TOTAL CASES= 256)



FIGURE 12
DISTRIBUTION OF MOST COMMON PEDIATRIC MALIGNANCIES BY HISTOLOGY
2016 ANALYTIC CASES (TOTAL CASES= 256)

MALE ALL 22 (8.6%) Neuroblastoma 10 (3.91%) Hodgkin Lymphoma 9 (3.52%) AML 8 (3.13%) Nephroblastoma 7 (2.73%) Pilocytic Astrocytoma 7 (2.73%) Retinoblastoma 6 (2.34%) Osteosarcoma 5 (1.95%) Rhabdomyosarcoma 4 (1.56%) Medulloblastoma 4(1.56%)

FEMALE

ALL 22 (8.6%)
AML 6 (2.34%)
Retinoblastoma 6 (2.34%)
Neuroblastoma 4 (1.56%)
Nephroblastoma 4 (1.56%)
Osteosarcoma 4 (1.56%)
Rhabdomyosarcoma 4 (1.56%)
Ewing sarcoma 4 (1.56%)
Hodgkin lymphoma 3 (1.17%)
Medulloblastoma 3 (1.17%)

TABLE 9 PRIMARY SITE TABLE (INCLUDES MULTIPLE PRIMARIES) 2016

SITE	HISTOLOGY	ALL CASES	ADULTS		PEADIATRICS		
SIIE	(NOS - Not Otherwise Specified)	ALL CASES			MALE FEMALE		
	(NOS - NOT Other wise Specified)	3,000	1219	1,525	147	109	
LIP	Course on Call Considerate	8	5	3	0	0	
	Squamous Cell Carcinoma	1	5	2	0	0	
	Malignant Melanona	'	0	1	0	0	
TONGL		28	17	11	0	0	
	Carcinoma NOS	1	1	0	0	0	
	Squamous Cell Carcinoma In Situ	1	0	1	0	0	
	Squamous Cell Carcinoma Keratinizing Squamous Cell Carcinoma NOS	2 24	0 16	2 8	0	0	
	Squamous Cell Calcinoma NOS	24			_	U	
GUM		4	2	2	0	0	
	Squamous Cell Carcinoma	4	2	2	0	0	
FLOOR	R OF MOUTH	5	4	1	0	0	
	Adenoid Cystic Carcinoma	1	0	1	0	0	
	Squamous Cell Carcinoma NOS	4	4	0	0	0	
OTHER	PARTS OF MOUTH	37	16	20	1	0	
	Adenocarcinoma NOS	2	1	1	0	0	
	Basal Cell Carcinoma	1	1	0	0	0	
	Hibernoma	1	1	0	0	0	
	Invasive Carcinoma	1	0	1	0	0	
	Mucoepidermoid Carcinoma	1	0	1	0	0	
	Polymorphous Low Grade Adenocarcinoma	1	1	0	0	0	
	Squamous Cell Carcinoma In Situ	3 27	11	2 15	0	0	
	Squamous Cell Ca NOS	21	11	15	'	0	
SALIVA	ARY GLANDS, MAJOR	13	9	4	0	0	
	Acinar Cell Carcinoma	1	0	1	0	0	
	Adenocarcinoma	3	3	0	0	0	
	Carcinoma NOS	1	1	0	0	0	
	Glomus Tumor NOS	1	1	0	0	0	
	Leiomyosarcoma NOS	1	1	0	0	0	
	Malignant Melanoma	1	0	1	0	0	
	Mucoepidermoid Carcinoma	3	2	1	0	0	
	Solitary Fibrous Tumor	1	0	1	0	0	
	Squamous Cell Carcinoma Keratinizing	'	ı	0	0	0	
TONSI		1	1	0	0	0	
	Squamous Cell Carcinoma	1	1	0	0	0	
LARYN	ıx	20	18	2	0	0	
	Spindle Cell Carcinoma NOS	2	2	0	0	0	
	Spindle Cell Sarcoma	1	1	0	0	0	
	Spidle Cell Ca In Situ	1	1	0	0	0	
	Squamous Cell Carcinoma NOS	16	14	2	0	0	

SITE	HISTOLOGY	ALL CASES	AD	ULTS	PEAD	IATRICS
	(NOS - Not Otherwise Specified)		MALE	FEMALE	MALE	FEMALE
NASO	PHARYNX	70	53	15	2	0
	Carcinoma Anaplastic	3	3	0	0	0
	Carcinoma NOS	22	17	4	1	0
	Carcinoma Undifferentiated	17	13	4	0	0
	Cystic Hypersecretory Carcinoma	1	1	0	0	0
	Mucoepidermoid Carcinoma	1	1	0	0	0
	Squamous Cell Carcinoma Large Nnkerat.	10	6	4	0	0
	Squamous Cell Carcinoma	16	12	3	1	0
HYPO	PHARYNX	5	0	5	0	0
	Squamous Cell Carcinoma	5	0	5	0	0
ESOPH	AGUS	26	19	7	0	0
	Adenocarcinoma	8	7	1	0	0
	Adenoca With Neuroendocrine diff.	1	1	0	0	0
	Squamous Cell Carcinoma Keratinizing	1	1	0	0	0
	Squamous Cell Carcinoma NOS	16	10	6	0	0
	equamous con carementa 1100	10		Ü	Ŭ	O .
STOM		43	31	12	0	0
	Adenocarcinoma Intestinal Type	1	1	0	0	0
	Adenocarcinoma NOS	26	19	7	0	0
	Atypical Carcinoid Tumor	1	1	0	0	0
	Carcinoid Tumor	1	1	0	0	0
	Carcinoma Anaplastic	1	1	0	0	0
	Carcinoma Diffuse Type	1	1	0	0	0
	Carcinoma NOS	2	1	1	0	0
	Gastrointestinal Stromal Sarcoma	1	1	0	0	0
	Gastrointestinal Stromal Tumor	3	2	1	0	0
	Neoplasm Malignant	1	1	0	0	0
	Neuroendocrine Carcinoma	1	1	0	0	0
	Neurofibroma	1	0	1	0	0
	Signet Ring Cell Carcinoma	2	0	2	0	0
	Squamous Cell Carcinoma NOS	1	1	0	0	0
SMALL	INTESTINE	9	6	3	0	0
	Adenocarcinoma NOS	5	3	2	0	0
	Carcinoid Tumor	2	2	0	0	0
	Neoplasm Malignant	1	0	1	0	0
	Pleomorphic Carcinoma	1	1	0	0	0
COLON	N	139	70	69	0	2
	Adenocarcinoma In Situ	2	1	1	0	1
	Adenocarcinoma NOS	119	61	58	0	0
	Carcinoid Tumor NOS	2	1	1	0	1
	Carcinoma In Situ	1	1	0	0	0
	Carcinoma NOS	2	1	1	0	0
	Mucinous Adenocarcinoma	6	3	3	0	0
	Neoplasm Malignant	1	1	0	0	0
	Neuroendocrine Carcinoma	1	0	1	0	0
	Pseudomyxoma Peritonei	1	0	1	0	0
	Signet Ring Cell Carcinoma	2	0	2	0	0
	Villous Adenoma NOS	2	1	1	0	0

SITE HISTOLOGY	ALL CASES	AD	ULTS	PEAD	IATRICS
(NOS - Not Otherwise Specified)	7122 071020		FEM ALE		
RECTUM & RECTOSIGMOID JUNCTION	115	62	53	0	0
Adenocarcinoma In Situ Adenomatous Polyp	1	1	0	0	0
Mucinous Adenocarcinoma In Situ	1	1	0	0	0
Adenocarcinoma	105	54	51	0	0
Atypical Carcinoid Tumor	2	1	1	0	0
Carcinoid Tumor NOS	1	1	0	0	0
Carcinoma NOS	2	1	1	0	0
Mucinous Adenocarcinoma	1	1	0	0	0
Signet Ring Cell Ca	1	1	0	0	0
Squamous Cell Ca NOS	1	1	0	0	0
ANUS, ANAL CANAL, ANORECTUM	10	8	2	0	0
Adenocarcinoma	5	3	2	0	0
Squamous Cell Carcinoma NOS	5	5	0	0	0
LIVER, INTRAHEPATIC BILE DUCT	95	61	34	1	2
Adenocarcinoma NOS	5	3	2	0	0
Atypical Carcinoid Tumor	1	0	1	0	0
Carcinoid Tumor	1	1	0	0	0
Carcinoma NOS	5	1	3	0	1
Carcinoma Undifferentiated	1	0	1	0	0
Cholangiocarcinoma	5	3	2	0	0
Hemangiosarcoma	1	1	0	0	0
Hepatocellular Carcinoma	70	49	20	0	1
Hepatocellular Carcinoma Scirrhous	2	2	0	0	0
Klastin Tumor	1	0	1	0	0
Neoplasm Malignant	1	0	1	0	0
Neuroendocrine Carcinoma	2	0	2	0	0
Pleomorphic Carcinoma	1	1	0	0	0
Spindle Cell Carcinoma NOS	1	0	1	0	0
Hepatoblastoma	1	0	0	1	0
GALLBLADDER, EXTRAHEPATIC BILE DUCT	12	6	6	0	0
Adenocarcinoma NOS	9	3	6	0	0
Adenosquamous Carcinoma	1	1	0	0	0
Intracystic Papillary Adenoma	1	1	0	0	0
Invasive carcinoma	1	1	0	0	0
PANCREAS	50	26	24	0	0
Adenocarcinoma Intestinal Type	1	0	1	0	0
Adenocarcinoma NOS	28	18	10	0	0
Adenocarcinoma With Mixed Sub Types	1	1	0	0	0
Atypical Carcinoid Tumor	3	1	2	0	0
Carcinoid Tumor	1	1	0	0	0
Carcinoma	4	1	3	0	0
Cholangiocarcinoma	2	1	1	0	0
Hepatocellular Carcinoma NOS	1	0	1	0	0
Invasive Carcinoma	1	1	0	0	0
Mucinous Adenocarcinoma	1	0	1	0	0
Neoplasm Malignant	7	2	5	0	0

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL	ADULTS MALE FEI		PEADIATRIC MALE FEM	
BILE DUC		16	8	8	0	0
	Adenocarcinoma	11	6	5	0	0
	Cholangiocarcinoma Neroendocrine Carcinoma NOS	4	1	3	0	0
	Neroendocrine Carcinoma NOS	1	1	0	0	0
NASAL CA	VITY, MIDDLE EAR	8	4	4	0	0
	Osteosarcoma NOS	1	0	1	0	0
	Odontogenic Tumor Malignant Neopasm Malignant	1	0 1	1	0 0	0
	Malignant Melanoma NOS	1	0	1	0	0
	Carcinoma NOS	1	1	0	0	0
	Signet Ring Cell Carcinoma	1	0	1	0	0
	Adenocarcinoma	1	1	0	0 0	0
	Squamous Cell Carcinoma	'	1	0	U	0
LARYNX		20	18	2	0	0
	Squamous Cell Carcinoma NOS	16	14	2	0	0
	Squamous Cell Carcinoma In Situ NOS Spindle Cell Carcinoma NOS	1 2	1 2	0	0 0	0
	Spindle Cell Sarcoma	1	1	0	0	0
					-	
LUNG, BR	ONCHUS Adenocarcinoma NOS	81 33	52 15	28 18	1 0	0
	Squamous Cell Carcinoma NOS	13	10	3	0	0
	Small Cell Carcinoma	5	5	0	0	0
	Non-Samll Cell Carcinoma	6	5	1	0	0
	Carcinoma NOS	3	3	0	0	0
	Carcinoid	3 2	2 1	1	0	0
	Neoplasm Malignant Mucinous Adenocarcinoma	1	1	0	0 0	0
	Large Cell Neuroendocrine Carcinoma	1	0	1	0	0
	Synovial Sarcoma NOS	2	1	1	0	0
	Squamous Cell Carcinoma Keratinizing NOS	1	1	0	0	0
	Renal Cell Carcinoma NOS	1	1 1	0	0	0
	Pseudosarcomatous Carcinoma Primitive Neuroectodermal Tumor NOS	1	0	1	0 0	0
	Pleomorphic Carcinoma	1	1	0	0	0
	Neuroendocrine Carcinoma NOS	4	3	1	0	0
	Epithelioid Sarcoma	2	1	0	1	0
	Mesothelioma Malignant	1	1	0	0	0
OTHER RE	SPIRATORY & THORACIC	5	5	0	0	0
	Adenocarcinoma NOS	3	3	0	0	0
	Neuroblastoma NOS	1	1	0	0	0
	Sarcoma	1	1	0	0	0
PLEURA	Chondroblastic Osteosarcoma	1	1 1	0 0	0 0	0 0
BONE IO		-			-	
BUNE, JO	INTS, CARTILAGE Osteosarcoma	54 18	22 6	12 3	11 5	9 4
	Ewing Sarcoma	6	2	0	2	2
	Chondrosarcoma NOS	2	2	0	0	0
	Chondroblastic Osteosarcoma	4	0	0	2	2
	Spindle Cell Sarcoma	1	0	1	0	0
	Chordoma Giant Cell Tumor of Bone Malignant	3	2 3	1	0 0	0 1
	Giant Cell Tumor of Bone NOS	1	0	1	0	0
	Liposarcoma NOS	1	1	o	0	0
	Adamantinoma of Long Bone	1	0	1	0	0
	Squamous Cell Carcinoma NOS	3	3	0	0	0
	Synovial Sarcoma NOS	1	1	0	0	0
	Pleomorphic Carcinoma Adenoid Cystic Carcinoma	1	1 0	0	0 0	0
	Myxopapillary Ependymoma	2	0	1	1	0
	Small Cell Carcinoma NOS	1	0	0	1	0
	Kaposi Sarcoma	3	1	2	0	0
	33					

SITE HISTOLOGY	ALL	ADULT	S	PEADIAT	RICS
(NOS - Not Otherwise Specified)		MALE F	EMALE	MALE F	EMALE
BONE MARROW	248	99	68	41	40
B Lymphoblastic Leukemia/Lymphoma	26	5	1	9	11
Acute Myeloid Leukemia	65	25	26	8	6
Precursor Cell Lymphoblastic Leukemia NOS	43	13	3	14	13
Chronic Myeloid Leukemia	21	7	13	0	1
B-Cell Chronic Lymphocytic Leukemia/Small Acute Monocytic Leukemia	11 2	8 2	3	0 0	0
Chronic Myelomonocytic Leukemia NOS		0	1	0	0
Acute Promyelocytic Leukemia	4	2	1	0	1
Acute Myeloid Leukemia with Maturation	1	0	1	0	0
Acute Leukemia NOS	17	7	6	3	1
Acute Myeloid Leukemia Minimal Differentiation	3	2	1	0	0
Acute Myeloid Leukemia T-cell	1	1	0	0	0
Therapy-Related Acute Myeloid Leukemia NOS	1	1	0	0	0
Burkitt Cell Leukemia	10	3	2	4	1
Plasma Cell Leukemia	16	13	3	0	0
Myeloid Sarcoma	1	1	0	0	0
Essential Thrombocythemia	1	1	0	0	0
Lymphoid Leukemia NOS	3	1	1	0	1
Myelodysplastic/Myeloproliferative Neoplasm Unclassifiab		2	2	0	0
Myelodysplastic Syndrome NOS	3	1	1	0	1
Leukemia NOS	4	0	2	1	1
Hairy Cell Leukemia	4	3	1	0	0
Hypereosinophilic Syndrome	2	1	0	0	1
Acute Megakaryoblastic Leukemia	1	0	0	1	0
Juvenile Myelomonocytic Leukemia	1	0	0	0	1
Precursor B-Cell Lymphoblastic Leukemia MULTIPLE MYELOMA	2 28	0 18	0 10	1 0	1 0
Multiple Myeloma	26	17	9	0	0
Plasmacytoma Extramedullary	1	1	0	0	0
Plasmacytoma	1	0	1	0	0
·		ŭ		-	
OTHER HEMATOPOIETIC	41	15	17	4	5
Adenocarcinoma	2	2	0	0	0
Essential Thrombocytosis	7	3	2	1	1
Langerhans Cell Histocytosis	3	2	1	0	0
Myelodysplastic Syndrome Myelodysplastic/Myeloproliferative Neoplasm	12 3	3 2	6 1	2 0	1 0
Myeloproliferative Disease	8	1	5	0	2
Neuroblastoma NOS	1	Ö	0	1	0
Polycythemia Vera	3	1	2	0	0
Rhabdomyosarcoma NOS	1	0	0	0	1
Synovial Sarcoma Spindle Cell	1	1	0	0	0
SKIN (MELANOMA)	6	2	4	0	0
Acral Lentiginous Melanoma Malignant	1	0	1	0	0
Malignant Melanoma	5	2	3	0	0
-	40	0.5	0.4	•	
SKIN (NON MELANOMA)	49	25	21	2	1
Adenoid Cystic Carcinoma Basal Cell adenocarcinoma	6	0 4	1 2	0 0	0
Basal Cell Caecinoma In Situ	1	1	0	0	0
Basal Cell Carcinoma Nodular	10	5	5	0	0
Basal Cell Carcinoma NOS	9	3	6	0	0
Carcinoma NOS	1	1	0	0	0
Dermatofibrosarcoma	4	3	1	0	0
Ewing Sarcoma	1	1	0	0	0
Hemangiosarcoma	1	1	0	0	0
Leiomyosarcoma NOS	1	0	0	0	1
Rhabdomyosarcoma NOS	1	0	0	1	0
Sebaceous Adenocarcinoma	2	1	1	0	0
Spindle Cell Sarcoma	1	0	0	1	0
Squamous Cell Carcinoma	10	5	5	0	0

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL	ADULTS MALE FEMA		IATRICS E FEMALE
BREAST		406	3 4	03	0 0
	Invasive Duct Carcinoma	321			0 0
	Lobular Carcinoma	31	0		0 0
	Comedocarcinoma Noninfiltrating Papillary Carcinoma NOS	2 2	0 0		0 0
	Papillary Microcarcinoma	1	Ö		0 0
	Neoplasm Malignant	3	0	3	0 0
	Cribriform Carcinoma NOS	1	0		0 0
	Carcinoma NOS Intraductal Carcinoma Noninfiltrating NOS	12 13	0 0		0 0
	Invasive Ductal Ca Mixed With Other Types	2	0		0 0
	Metaplastic Carcinoma	1	0		0 0
	Phyllodes Tumor Borderline	1	0		0 0
	Phyllodes Tumor Malignant	2	0		0 0
	Spindle Cell Carcinoma NOS Adenocarcinoma	1 2	0 0		0 0 0 0
	Lobular Carcinoma In Situ	4	0		0 0
	Mucinous Adenocarcinoma	3	0		0 0
	Spindle Cell Sarcoma	1	0		0 0
	Sarcoma NOS	2	0		0 0
CEDVIX LI	Granular Cell Tumor Malignant	1	0		0 0
CERVIX U	Adenocarcinoma Endocervical Type	39 1	0 0		0
	Adenocarcinoma	5	0		0 0
	Carcinoma	1	0		0 0
	Choriocarcinoma NOS	2	0		0 0
	Endometrioid Adenocarcinoma NOS	3	0		0 0
	Leiomyosarcoma NOS	3	0		0 0
	Mullerian Mixed Tumor	1	0		0 0
	Neoplasm Malignant	1	0		0 0
	Papillary Serous Cystadenocarcinoma	1	0 0		0 0
	Signet Ring Cell Carcinoma Small Cell Carcinoma	1	0		0 0
	Squamous Cell Carcinoma Large Nonkeratinizing NOS	4	0		0 0
	Squamous Cell Carcinoma NOS	8	0		0 0
	Squamous Cell Carcinoma In Situ NOS	1	0		0 0
	Squamous Intraepithelial Neoplasia Grade III	6	0	6	0 0
CORPUS	ITERI	80	0	80	о о
CORFUS	Adenocarcinoma NOS	24	0		0 0
	Carcinoma Anaplastic NOS	1	Ö		0 0
	Carcinoma NOS	1	0	1	0 0
	Endometrial Stromal Sarcoma Low Grade	1	0		0 0
	Endometrioid Adenocarcinoma NOS	40 1	0 0		0 0
	Endometrioid Adenofibroma NOS Leiomyosarcoma NOS	1	0		0 0
	Mullerian Mixed Tumor	2	Ö		0 0
	Neoplasm Malignant	1	0	1	0 0
	Placental Site Throphoblastic Tumor	1	0		0 0
	Serous Cystadenocarcinoma NOS	2	0		0 0
	Squamous Cell Carcinoma NOS Squamous Intraepithelial Neoplasia Grade III	1	0 0		0 0
	Stromal Sarcoma NOS	1	Ö		0 0
OVARY		56	0		0 0
	Adenocarcinoma	9	0		0 0
	Adenofibroma NOS Carcinoid Tumor NOS	1	0 0		0 0
	Carcinoma	2	0		0 0
	Carcinoma Undifferentiated NOS	1	0	1	0 0
	Fibrosarcoma NOS	1	0		0 0
	Granulosa Cell Tumor Malignant	2	0		0 0
	Lipid Cell Tumor of Ovary Malignant Serous Tumor	1	0 0		0 0
	Malignant Teratoma Undifferentiated	1	0		0 0
	Mesothelioma Malignant	1	0		0 0
	Mixed Germ Cell Tumor	1	0	1	0 0
	Mucinous Adenocarcinoma	3	0		0 0
	Mucinous Cystadenoma NOS	1	0		0 0
	Mucinous Cystic Tumor of Borderline Malignancy Mullerian Mixed Tumor	1 1	0 0		0 0
	Neoplasm Malignant	3	0		0 0
	Papillary Serous Cystadenocarcinoma	1	Ö		0 0
	Serous Cystadenocarcinoma	15	0		0 0
	Serous Papillary Cystic Tumor of Borderline Malignancy	1	0		0 0
	Serous Surface Papillary Carcinoma	1	0		0 0
	Serous Surface Papillary Tumor of Borderline Malignancy Sex Cord-Gonadal Stromal Tumor NOS	1	0 0		0 0
	Teratoma Malignant NOS	1	0		0 0
	Yolk Sac Tumor	4	Ö	_	0 0

SITE	HISTOLOGY	ALL	ADULTS	3	PEADIATR	ICS
	(NOS - Not Otherwise Specified)		MALE FE	MALE	MALE FE	MALE
RETROP	ERITONEUM, PERITONEUM	15	8	7	0	0
	Adenocarcinoma NOS	4	1	3	0	0
	Choriocarcinoma NOS	1	1	0	0	0
	Dysgerminoma	1	0	1	0	0
	Liposarcoma NOS	2	2	0	0	0
	Liposarcoma Well Differentiated	1	1	0	0	0
	Mesothelioma Malignant	1	1	0	0	0
	Paraganglioma Malignant	1	1	0	0	0
	Pseudomyxoma Peritonei	1	1	0	0	0
EYE	Serous Cystadenocarcinoma NOS	3 19	0 2	3 0	0 9	0
EIE	Retinoblastoma	12	0	0	6	8
	Retinoblastoma Differentiated	12	0	0	0	1
	Retinoblastoma Undifferentiated	1	0	0	1	0
	Adenoid Cystic Carcinoma	1	1	0	0	0
	Carcinoma NOS	1	1	0	0	0
	Rhabdomyosarcoma NOS	3	0	0	2	1
CONNEC	TIVE, SUBCUTEANEOUS, SOFT TISSUES	45	25	20	0	0
COMMEC	Chondrosarcoma NOS	45 1	25 0	20	0 0	0 0
	Clear Cell Sarcoma NOS	1	1	0	0	0
	Dermatofibrosarcoma NOS	4	2	2	0	0
	Epithelioid Hemangioendothelioma NOS	1	1	0	0	0
	Epithelioma Malignant	1	0	1	0	0
	Ewing Sarcoma	4	2	2	0	0
	Fibroblastic Liposarcoma	1	1	0	0	0
	Fibrosarcoma NOS	1	1	0	0	0
	Giant Cell Tumor of Soft Parts	1	0	1	0	0
	Leiomyosarcoma	2	1	1	0	0
	Liposarcoma NOS	1	1	0	0	0
	Malignant Myoepithelioma	1	0	1	0	0
	Mucinous Adenocarcinoma	1	0	1	0	0
	Myofibroblastic Sarcoma	1	1	0	0	0
	Myxoid Chondrosarcoma	3	3	0	0	0
	Myxoid Liposarcoma	2	2	0	0	0
	Myxosarcoma	1	1	0	0	0
	Neoplasm Malignant	1	0	1	0	0
	Periosteal Osteosarcoma	1	1	0	0	0
	Primitive Neuroectodermal Tumor NOS	1	0	1	0	0
	Sarcoma NOS	5	3	2	0	0
	Spindle Cell Carcinoma NOS	4	2	2	0	0
	Spindle Cell Sarcoma Squamous Cell Carcinoma	3	1 0	2	0 0	0
	Synovial Sarcoma	1	1	0	0	0
VULVA	Syriovial Salcottia	4	Ó	4	0	0
102171	Squamous Cell Carcinoma NOS	2	0	2	0	0
	Adenocarcinoma NOS	1	0	1	0	0
	Squamous Intraepithelial Neoplasia Grade III	1	0	1	0	0
TESTIS		27	26	0	1	o
	Seminoma	7	7	0	0	0
	Embryonal Carcinoma NOS	2	2	0	0	0
	Germinoma	4	4	0	0	0
	Mixed Germ Cell Tumor	10	9	0	1	0
	Squamous Cell Carcinoma NOS	1	1	0	0	0
	Teratoma Malignant	3	3	0	0	0
OTHER M	IALE/FEMALE GENITAL CANCERS	5	3	2	0	0
	Carcinoma NOS	1	0	1	0	0
	Embryonal Rhabdomyosarcoma NOS	1	1	0	0	0
	Sarcoma NOS	1	1	0	0	0
	Squamous Cell Carcinoma NOS	1	1	0	0	0
	Trophoblastic Placenta Malignant	1	0	1	0	0

SITE	HISTOLOGY	ALL	ADU	LTS	PEADIA	TRICS
DESCE	(NOS - Not Otherwise Specified)			FEMALE	MALE	FEMALE
PROSTA	TE Adenocarcinoma NOS	59 58	59 58	0	0 0	0 0
	Carcinoma NOS	1	1	0	0	0
KIDNEY		97	56	28	8	5
	Clear Cell Adenocarcinoma	13	9	4	0	0
	Renal Cell Carcinoma Chromophobe Type	10	5	5	0	0
	Papillary Adenocarcinoma	1	1	0	0	0
	Transitional Cell Carcinoma	2	2	0	0	0
	Carcinoma NOS Nephroblastoma	2 11	0	2	0 7	0 4
	Malignant Rhabdoid Tumor	1	0	0	0	1
	Renal Cell Carcinoma NOS	55	38	16	1	0
	Liposarcoma NOS	1	0	1	0	0
	Pseudosarcomatous Carcinoma	1	1	0	0	0
URINARY	BLADDER	92	75	14	3	0
	Adenocarcinoma NOS	1	1	0	0	0
	Carcinoma NOS	2	2	0	0	0
	Desmoplastic Small Round Cell Tumo Epithelioma Malignant	1	0	0	1 0	0 0
	Embryonal Rhabdomyosarcoma Nos	2	0	0	2	0
	Invasive Micropapillary Carcinoma	1	1	0	0	0
	Neoplasm Malignant	1	1	0	0	0
	Papillary Transitional Cell Carcinoma	33	30	3	0	0
	Papillary Trans. Cell Neoplasm Of Low Malignant Potentia	1	1	0	0	0
	Pseudosarcomatous Carcinoma	1	1	0	0	0
	Squamous Cell Carcinoma	1	1	0	0	0
	Transitional Cell Carcinoma In SITU	5 42	5 32	0	0	0
OTHER I	Transitional Cell Carcinoma NOS URINARY ORGAN	1	32 1	10 0	0	o
0111_11	Squamous Cell Carcinoma NOS	1	1	o	0	0
BRAIN		463	125	292	29	17
	Adenocarcinoma NOS	1	1	0	0	0
	Astrocytoma	6	3	0	1	2
	Astrocytoma Anaplastic	1	1	0	0	0
	Atypical Meningioma Cavernous Hemangioma	1	0	7	0 0	0
	Chordoma NOS	2	0	1	1	0
	Choroid Plexus Carcinoma	1	1	0	0	0
	Craniopharyngioma	3	0	1	0	2
	Dysembryoplastic Neuroepithelial Tumor	4	2	1	1	0
	Ependymoma	2	0	0	2	0
	Ependymoma Anaplastic	1	0	0	1	0
	Ewing Sarcoma Ganglioglioma NOS	1	1	0	0 3	0 1
	Ganglioglioma Anaplastic	4	0	1	3 1	2
	Giant Cell Astrocytoma Malignant	1	0	Ö	1	0
	Giant Cell Tumor Of Bone Malignant	1	0	1	0	0
	Glioblastoma	19	11	6	1	1
	Glioma Benign	1	1	0	0	0
	Glioma Malignant	13	6	5	2	0
	Gliosarcoma	1	0 1	1	0	0
	Hemangioblastoma Medulloblastoma	8	1	0	4	0 3
	Meningioma Malignant	7	2	5	0	0
	Meningioma NOS	40	11	29	0	0
	Meningiomatosis NOS	1	1	0	0	0
	Mixed Glioma	3	3	0	0	0
	Neoplasm Uncertain Whether Benign Or Malignant	1	1	0	0	0
	Neuroepithelioma NOS	2	0	0	2	0
	Neurilemoma NOS Oligodendroglioma	10 5	2	8 2	0 0	0
	Oligodendroglioma Anaplastic	4	ა 1	3	0	0
	Medullary Carcinoma	9	2	5	0	2
	Neoplasm Malignant	2	0	2	0	0
	Osteosarcoma NOS	1	0	1	0	0
	Oxyphilic Adenocarcinoma	3	0	3	0	0
	Papillary Adenocarcinoma	171	43	124	2	2
	Papillary Carcinoma Columnar Cell	2	0	2	0	0
	Papillary Carcinoma Follicular Variant Papillary Carcinoma NOS	19 35	3 9	16 26	0 0	0
	Papillary Microcarcinoma	19	5	14	0	0
	r apiliary Microcarcinoma	19		14	U	U

Patichard Neuroeucochamil Tumor	SITE	HISTOLOGY	ALL	ADULTS		PEADIA	ATRICS
Pilocytic Astrocytoms		(NOS - Not Otherwise Specified)					
Pleomorphic Xanthosstocytoms		•					
Pasammomstaus Meningioran 2							
Follicular Adenocarcinoma Follicular Adenocarcinoma Follicular Adenocarcinoma Follicular Adenocarcinoma Follicular Arcinema (Fc), Encapsulated Follicular Tyrproid Carcinema (Fc), Encapsulated Follicular Carcinema (Fc), Encapsulared							
Follicular Carcinoma Minimally Invesive Follicular Tryord Carcinoma (FIC). Encepsulated Follicular Tryord Carcinoma (FIC). Encepsulated Follicular Tryord Carcinoma (FIC). Encepsulated Follicular Tryord Carcinoma Address Carcinoma Address Carcinoma Address Carcinoma Address Carcinoma Address Carcinoma Endocrino Tumor, Functioning, NOS, Malignant Endocrino Tumor, Functioning, NOS, Function, Functioning, NOS, Function, Functioning, NOS, Function, Functioning, NOS, Function, Funct			1				
Follicular Thyroid Carcinoma (Ftc). Encappulated plane of PTC							
Investive Encapsulated Folloular Variant Of PTC							
OTHER ENDOCRINE GLÁNDS							
Adrenal Controlal Carcinoma Endocrine Turnor, Functioning, NOS, Malignant Endocrine Turnor, Functioning, NOS, Malignant Endocrine Turnor, Functioning, NOS, Malignant Malignant Rhabedod Turnor Malignant Rhabedod Turnor Malignant Rhabedod Turnor Neuroblastorna NOS Puturary Carcinoma NOS Puturary Carcinoma NOS Thymoma NOS Puturary Carcinoma NOS Thymoma NOS Nodular Sclerosia Nodu	OTHER E						
Endocrine Tumor, Functioning, NOS, Malignant 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		Adenoma NOS	1	0	1	0	0
Epithelioid Hemangicendothelio Ma Malignant Rhatoldof Tumor Meningothelial Meningioma 1 0 0 1 0 0 0 1 Meningothelial Meningioma 1 0 0 1 0 0 0 0 1 Meningothelial Meningioma 1 0 0 1 0 0 0 0 0 1 Neurodisastroma NOS 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			5				
Mailgnant Rhabdoid Tumor			1				
Meningothelial Meningioma 1			1				
Pituliary Carcinoma NOS			1				
Thymoma NOS Thymoma Type B3 Malignant Thymoma Type B4 Malignant Thymoma Type Type Malignant Thymoma Type Type Malignant Thymoma Type Type Type Type Type Type Type Type		Neuroblastoma NOS	7	0	0	5	2
Thymoran Type B2 Malignant			1				
Thymoma Type B3 Malignant IYMPH NODES (HODKINNS LYMPHOMA) 121 53 49 13 6 Nodular Sclerosia Callular Phase Nodular Sclerosia Callular			1				
LYMPH NODES (HODGKIN'S LYMPHOMA)		The state of the s	1				
Nodular Scierosis Cellular Phase 2	LYMPH						
Nodular Lymphocyte Predominance 6							
Lymphocyte Rich 2		Nodular Sclerosis Cellular Phase	2	0	2	0	0
Lymphocyte Depletion Hodgkin's Lymphoma NOS							
Hodgkin's Lymphoma NOS							
Mixed Cellularity 6							
LYMPH NODES (NON HODGKIN'S LYMPHOMA)							
Burkitt Lymphoma CUTANEOUS T-CELL LYMPHOMA NOS 2	LYMPH N						
CUTANEOUS T-CELL LYMPHOMA NOS Follicular Lymphoma Grade 1 Follicular Lymphoma Grade 2 Follicular Lymphoma Grade 2 Follicular Lymphoma Grade 3 Follicular Lymphoma Grade 3 Follicular Lymphoma NoS Follicular Rymphoma NoS Follicular Rymphoma NoS Follicular Rymphoma NoS Follicular Rymphoma NoS Follicular Lymphoma NoS Foll		Anaplastic Large Cell Lymphoma T Cell	3	0	2	1	0
Follicular Lymphoma Grade 1							
Follicular Lymphoma Grade 2 Follicular Lymphoma Grade3 Follicular lymphoma NOS			2				
Follicular Lymphoma Grade3			1				
Follicular lymphoma NOS			1				
Malignant Lymphoma Non-Hodgkin NOS 34 21 13 0 0 Malignant Lymphoma Small B 1 0 1 0 0 0 Marginal Zone B-Cell Lymphoma NOS 4 1 3 0 0 Murca T-Cell Lymphoma Nasal and Nasal Type 4 1 3 0 0 NK/T-Cell Lymphoma Nasal and Nasal Type 3 3 0 0 0 NK/T-Cell Lymphoma Nasal and Nasal Type 3 3 0 0 0 0 NK/T-Cell Lymphoma Nasal and Nasal Type 3 3 0							
Malignant Lymphoma NOS 11 3 7 1 0 Malignant Lymphoma Small B 1 0 1 0 0 Marginal Zone B-Cell Lymphoma NoS 4 1 3 0 0 0 Mkure T-Cell Lymphoma Nasal and Nasal Type 19 8 11 0 0 0 NK/T-Cell Lymphoma Nasal and Nasal Type 3 3 0		Large B-Cell Diffuse	66	41	21	1	3
Malignant Lýmphoma Small B 1 0 1 0 0 Marginal Zone B-Cell Lymphoma 4 1 3 0 0 Mature T-Cell Lymphoma 4 1 3 0 0 MKDOSIS Fungoides 19 8 11 0 0 0 NKT-Cell Lymphoma Nasal and Nasal Type 3 3 0 0 0 0 PRECURSOR CELL LYMPHOBLASTIC LYMPHOMA 1 1 0 0 1 0							
Marginal Zone B-Cell Lymphoma NOS 4 1 3 0 0 Mature T-Cell Lymphoma 4 1 3 0 0 Mycosis Fungoides 19 8 11 0 0 0 NK/T-Cell Lymphoma Nasal and Nasal Type 3 3 0 0 0 0 PRECURSOR CELL LYMPHOBLASTIC LYMPHOMA 1 0 0 1 0 <			11				
Mature T-Cell Lymphoma 4 1 3 0 0 Mycosis Fungoides 19 8 11 0 0 NK/T-Cell Lymphoma Nasal and Nasal Type 3 3 0 0 0 PRECURSOR CELL LYMPHOBLASTIC LYMPHOMA 1 0 0 1 0 Sezary Syndrome 1 1 0 0 1 0 UNKNOWN OR ILL-DEFINED 49 24 16 5 4 Alveolar Rhabdomyosarcoma 1 0 0 1 0 0 Alveolar Rhabdomyosarcoma 1 1 0 0 1 0 0 0 0 Alveolar Rhabdomyosarcoma 1 1 0			1				
Mycosis Fungoides 19							
PRECURSÓR CELL LYMPHOBLASTIC LYMPHOMA		· ·	19	8	11	0	
Sezary Syndrome			3		0	0	
UNKNOWN OR ÎLL-DEFINED			1				
Alveolar Rhabdomyosarcoma Adenocarcinoma NOS Alk Positive Large Bcell Lymphoma Angiomatoid Fibrous Histicoyt Malignant Basosquamous Carcinoma Carcinoma NOS Algeory and the provided Historyt Malignant Basosquamous Carcinoma Carcinoma NOS Algeory and the provided Historyt Malignant Carcinoma NOS Dedifferentiated Liposarcoma Ewing Sarcoma Clomangioma Clomangioma Algeory and the provided Historyte Malignant Neuroblastoma NOS Algeory and the provided Historyte Malignant Neuroendocrine Carcinoma Algeory and the provided Historyte Malignant Algeory and the	IINKNOW		19				
Adenocarcinoma NOS	Sitiator		1				
Alk Positive Large Bcell Lymphoma Angiomatoid Fibrous Histiccyt Malignant Basosquamous Carcinoma Carcinoma NOS Dedifferentiated Liposarcoma Ewing Sarcoma Glomangioma Ewing Sarcoma Glomangioma Hemangiosarcoma Large Cell Neuroendocrine Carcinoma Leiomyosarcoma NOS Malignant Fibrous Histiccytoma Neuroblastoma NOS Neuroblastoma NOS Neuroblastoma Malignant Nodular Hidradenoma Malignant Paraganglioma Malignant Paraga			4				
Basosquamous Carcinoma 1 1 0 0 0 Carcinoma NOS 4 1 3 0 0 Dedifferentiated Liposarcoma 1 1 0 0 0 Ewing Sarcoma 2 2 2 0 0 0 Glomangiosarcoma 1 0 1 0 0 0 Hemangiosarcoma 1 1 0 0 0 0 Large Cell Neuroendocrine Carcinoma 1 1 0 0 0 0 Leiomyosarcoma NOS 1 0 1 0 0 0 0 Malignant Fibrous Histicoytoma 1 1 1 0 0 0 0 Meuroblastoma NOS 6 0 0 4 2 0 0 4 2 Neuroendocrine Carcinoma 1 1 0 0 0 0 4 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0			1	1	0	0	
Carcinoma NOS 4 1 3 0 0 Dedifferentiated Liposarcoma 1 1 0 0 0 Ewing Sarcoma 2 2 2 0 0 0 Glomangioma 1 0 1 0 0 0 Hemangiosarcoma 1 1 0 0 0 0 Large Cell Neuroendocrine Carcinoma 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			1		1	0	
Dedifferentiated Liposarcoma 1		•	1				
Ewing Sarcoma 2 2 0 0 0 Glomangioma 1 0 1 0 0 Hemangiosarcoma 1 1 0 0 0 Large Cell Neuroendocrine Carcinoma 1 1 0 0 0 Leiomyosarcoma NOS 1 0 1 0 0 0 Malignant Fibrous Histiocytoma 1 1 0 0 0 0 Meuroblastoma NOS 6 0 0 4 2 1 1 0 0 0 0 Neoplasm Malignant 2 1 1 0 <td< td=""><td></td><td></td><td>4</td><td></td><td></td><td></td><td></td></td<>			4				
Glomangioma		•	2				
Hemangiosarcoma		-	1				
Leiomyosarcoma NOS 1 0 1 0 0 Malignant Fibrous Histiocytoma 1 1 0 0 0 Neuroblastoma NOS 6 0 0 4 2 Neoplasm Malignant 2 1 1 0 0 Neuroendocrine Carcinoma 1 0 1 0 0 Nodular Hidradenoma Malignant 1 1 0 0 0 Nodular Hidradenoma Malignant 1 1 0 0 0 Osteosarcoma NOS 1 1 0 0 0 Paraganglioma Malignant 1 1 0 0 0 Plasmablastic Lymphoma (2010) 1 1 0 0 0 Primitive Neuroectodermal Tumor No 2 0 2 0 0 Rhabdomyosarcoma NOS 1 1 0 0 0 Sarcoma NOS 2 2 0 0 0 Sertoli Cell Tumor NOS 3 1 1 0 0 0 <t< td=""><td></td><td></td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td></t<>			1	1	0	0	0
Malignant Fibrous Histiocytoma 1 1 0 0 0 Neuroblastoma NOS 6 0 0 4 2 Neoplasm Malignant 2 1 1 0 0 Neuroendocrine Carcinoma 1 0 1 0 0 Neuroendocrine Carcinoma 1 0 1 0 0 Nodular Hidradenoma Malignant 1 1 0 0 0 Osteosarcoma NOS 1 1 0 0 0 Paraganglioma Malignant 1 1 0 0 0 Plasmablastic Lymphoma (2010) 1 1 0 0 0 Primitive Neuroectodermal Tumor No 2 0 2 0 0 Rhabdomyosarcoma NOS 1 1 0 0 0 Sarcoma NOS 2 2 2 0 0 Sertoli Cell Tumor NOS 1 0 0 0 1 Small Cell Carcinoma NOS 3 1 1 0 0 0 <		-	1				
Neuroblastoma NOS 6 0 0 4 2 Neoplasm Malignant 2 1 1 0 0 Neuroendocrine Carcinoma 1 0 1 0 0 Nodular Hidradenoma Malignant 1 1 0 0 0 Nodular Hidradenoma Malignant 1 1 0 0 0 Osteosarcoma NOS 1 1 0 0 0 Paraganglioma Malignant 1 1 0 0 0 Paraganglioma Malignant 1 1 0 0 0 Plasmablastic Lymphoma (2010) 1 1 0 0 0 Primitive Neuroectodermal Tumor No 2 0 2 0 0 Rhabdomyosarcoma NOS 1 1 1 0 0 0 Sarcoma NOS 2 2 2 0 0 0 Sertoli Cell Tumor NOS 1 0 0 0 1 Serous Cystadenocarcinoma 1 1 0 0 0			1				
Neoplasm Malignant 2 1 1 0 0 Neuroendocrine Carcinoma 1 0 1 0 0 Nodular Hidradenoma Malignant 1 1 0 0 0 Osteosarcoma NOS 1 1 0 0 0 Paraganglioma Malignant 1 1 0 0 0 Plasmablastic Lymphoma (2010) 1 1 0 0 0 Primitive Neuroectodermal Tumor No 2 0 2 0 0 Rhabdomyosarcoma NOS 1 1 0 0 0 Sarcoma NOS 2 2 0 0 0 Sertoli Cell Tumor NOS 1 1 0 0 0 1 Small Cell Carcinoma NOS 3 1 1 0 0 0 Serous Cystadenocarcinoma 1 1 0 0 0 Squamous Cell Carcinoma 1 1 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0			1				
Neuroendocrine Carcinoma 1 0 1 0 0 Nodular Hidradenoma Malignant 1 1 0 0 0 Osteosarcoma NOS 1 1 0 0 0 Paraganglioma Malignant 1 1 0 0 0 Plasmablastic Lymphoma (2010) 1 1 0 0 0 Primitive Neuroectodermal Tumor No 2 0 2 0 0 Rhabdomyosarcoma NOS 1 1 0 0 0 Sarcoma NOS 2 2 2 0 0 0 Sertoli Cell Tumor NOS 1 0 0 0 1 Small Cell Carcinoma NOS 3 1 1 0 0 1 Serous Cystadenocarcinoma 1 1 0 0 0 0 Squamous Cell Carcinoma 1 1 0 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0							
Nodular Hidradenoma Malignant 1 1 0 0 0 Osteosarcoma NOS 1 1 0 0 0 Paraganglioma Malignant 1 1 0 0 0 Plasmablastic Lymphoma (2010) 1 1 0 0 0 Primitive Neuroectodermal Tumor No 2 0 2 0 0 Rhabdomyosarcoma NOS 1 1 0 0 0 Sarcoma NOS 2 2 2 0 0 0 Sertoli Cell Tumor NOS 1 0 0 0 1 Small Cell Carcinoma NOS 3 1 1 0 0 1 Serous Cystadenocarcinoma Squamous Cell Carcinoma 1 1 0 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0			1				
Paraganglioma Malignant 1 1 0 0 0 Plasmablastic Lymphoma (2010) 1 1 0 0 0 Primitive Neuroectodermal Tumor No 2 0 2 0 0 Rhabdomyosarcoma NOS 1 1 0 0 0 Sarcoma NOS 2 2 2 0 0 0 Sertoli Cell Tumor NOS 1 0 0 0 1 Small Cell Carcinoma NOS 3 1 1 0 0 Serous Cystadenocarcinoma 1 1 0 0 0 Squamous Cell Carcinoma 1 1 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0			1	1	0	0	
Plasmablastic Lymphoma (2010) Primitive Neuroectodermal Tumor No Rhabdomyosarcoma NOS Sarcoma NOS Sertoli Cell Tumor NOS Small Cell Carcinoma NOS Serous Cystadenocarcinoma Squamous Cell Carcinoma Spindle Cell Sarcoma 1 1 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0		Osteosarcoma NOS	1		0	0	0
Primitive Neuroectodermal Tumor No 2 0 2 0 0 Rhabdomyosarcoma NOS 1 1 0 0 0 Sarcoma NOS 2 2 0 0 0 Sertoli Cell Tumor NOS 1 0 0 0 1 Small Cell Carcinoma NOS 3 1 1 0 1 Serous Cystadenocarcinoma 1 1 0 0 0 Squamous Cell Carcinoma 1 1 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0		Paraganglioma Malignant	1	1	0	0	0
Rhabdomyosarcoma NOS 1 1 0 0 0 Sarcoma NOS 2 2 0 0 0 Sertoli Cell Tumor NOS 1 0 0 0 1 Small Cell Carcinoma NOS 3 1 1 0 1 Serous Cystadenocarcinoma 1 1 0 0 0 Squamous Cell Carcinoma 1 1 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0		Plasmablastic Lymphoma (2010)	1	1	0	0	0
Sarcoma NOS 2 2 0 0 0 Sertoli Cell Tumor NOS 1 0 0 0 1 Small Cell Carcinoma NOS 3 1 1 0 1 Serous Cystadenocarcinoma 1 1 0 0 0 Squamous Cell Carcinoma 1 1 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0		Primitive Neuroectodermal Tumor No	2	0	2	0	0
Sertoli Cell Tumor NOS 1 0 0 0 1 Small Cell Carcinoma NOS 3 1 1 0 1 Serous Cystadenocarcinoma 1 1 0 0 0 Squamous Cell Carcinoma 1 1 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0		Rhabdomyosarcoma NOS	1	1	0	0	0
Small Cell Carcinoma NOS 3 1 1 0 1 Serous Cystadenocarcinoma 1 1 0 0 0 Squamous Cell Carcinoma 1 1 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0		Sarcoma NOS	2	2	0	0	0
Serous Cystadenocarcinoma 1 1 0 0 0 Squamous Cell Carcinoma 1 1 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0		Sertoli Cell Tumor NOS	1	0	0	0	1
Squamous Cell Carcinoma 1 1 0 0 0 Spindle Cell Sarcoma 5 2 3 0 0			3	1	1	0	1
Spindle Cell Sarcoma 5 2 3 0 0		Serous Cystadenocarcinoma	1		0		
			1				
			5	2	3	0	0

TABLE 10 MULTIPLE PRIMARY SITE TABLE 2016

DDIM	ARY SITE	HISTOLOGY		OTHER PRIMARIES	ALL		
		IOS - Not Otherwise Spe	oified)	(PREVIOUS OR CONCURRENT)		MALE	FEMALE
	2010 (1)	103 - Not Otherwise Spe	cilled)	(FREVIOUS OR CONCORRENT)	169	72	97
					103	12	31
LIP					1	0	1
	Squamous (Cell Carcinoma	Tong	ue - Sq Cell Carcinoma	1	0	1
	oquamous (Jon Garonioma	rong	ac eq con caromema	•	Ŭ	·
TONG					2	2	0
	•	Cell Carcinoma		oharynx - Carcinoma	1	1	0
	Squamous (Cell Carcinoma	Liver	- Hepatocellular Carcinoma	1	1	0
MOUT	'LJ				4	2	2
WICCI	Adenocarcir	noma	Stoma	ach- Sq Cell Carcinoma	1	1	0
	7100110001011	Toma		i - Adenocarcinoma	•	•	· ·
	Squamous (Cell Carcinoma		Palat - Sq Cell Carcinoma	1	0	1
	•	moid Carcinoma		pid - Papillary Adenocarcinoma	1	0	1
	•	Cell Carcinoma		orm Sinus - Sq Cell Ca	1	1	0
			, ,				
EYE					1	1	0
	Carcinoma		Saliva	ary Glands - Adenocarcinoma	1	1	0
	Odromoma		Canve	ary Siarias Macriocaroliloma		•	J
GALLE	BLADDER				1	0	1
	Adenocarcir	noma	Large	B-Cell Lymphoma	1	0	1
			3.	, , ,			
ESOPI	HAGUS				1	1	0
	Adenocarcin	noma	Luna	- Sq Cell Carcinoma	1	1	Ö
07014			. 3	- 1			
STOM			T I	id Desiller Adecessions	2	2	0
	Carcinoid T			oid - Papillary Adenocarcinoma ler - Papillary Urothelial Ca	1	1 1	0
	Carcinoma	Diffuse Type	Diauu	lei - Fapiliary Orotheliai Ca		1	U
SMALI	LINTESTINE				1	0	1
	Adenocarcir	noma	Rectu	ım - Adenocarcinoma	1	0	1
						_	_
COLO			Ol-i	DI O-II Oi	8	4	4
	Adenocarcin			Basal Cell Carcinoma	1	1	0
	Adenocarcir Adenocarcir			y - Renal Cell Carcinoma - Adenocarcinoma	1	0 1	0
	Adenocarcir			- Adenocarcinoma - Sq Intraepithelial Neoplasia	1	0	1
	Adenocarcir			ate - Adenocarcinoma	1	1	0
	Adenocarcin			- Carcinoid Tumor	1	1	0
		crine Carcinoma	_	pharynx - Carcinoma	1		1
	Villous Ader			st - Invasive Ductal Ca	1	0	1
	VIIIOUS AGEI	IOITIa	Dieas	si - Invasive Duciai Ca		0	
RECTU		IGMOID JUNCTION			8	3	5
	Adenocarcir			y - Renal Cell Ca	1	1	0
	Adenocarcir	noma		/ - Serous Papillary Carcinoma	1	0	1
	A -1			- Meningioma		_	
	Adenocarcin			oid - Papillary Adenocarcinoma	1	0	1
	Adenocarcin			x Uteri - Sq Cell Carcinoma	1	0	1
	Adenocarcir Adenocarcir			nic Lymphocytic leukemia Ier - Papillary Urothelial Carcinon	1	0 1	1
	Adenocarcir			iei - Papillary Orotheliai Carcinon iid - Papillary Adenocarcinoma	1	0	1
	Adenocarcir			oid - Papillary Adenocarcinoma	1	1	0
			,	ap.mary recorded and morning			

PRIMARY SIT	E HISTOLOGY	OTHER PRIMARIES	ALL		
2016	(NOS - Not Otherwise Sp	ecified) (PREVIOUS OR CONCURRENT)	CASES	MALE	FEMALE
CERVIX UTER	1		4	0	4
	ant Neoplasm	Ovary - Papillary Serous Cystadenoma	=	0	1
g.	ia	Hodgkin's Lymphoma	·	Ū	·
	carcinoma	Breast - Invasive Ductal Carcinoma	1	0	1
•	nous Cell Carcinoma s Cystadenoma	Breast - Lobular Carcinoma Breast - Invasive Ductal Carcinoma	1	0	1
Serou	s Cystadenoma	Breast - invasive Ductar Carcinoma		U	•
LIVED INTRA	HEPATIC BILE DUCT		6	3	3
	ocellular Carcinoma	Rectum - Adenocarcinoma	1	0	1
	ocellular Carcinoma	Tonsil - Large B-Cell Lymphoma	1	0	1
	ocellular Carcinoma ocellular Carcinoma	Thyroid - Papillary Carcinoma Colon - Adenocarcinoma	1	1 1	0
riopati	occinatar Caronionia	Thyroid - Papillary Carcinoma	•	•	Ŭ
	ocellular Carcinoma	Prostate - Adenocarcinoma	1	1	0
Neopia	asm Malignant	Ovary - Adenocarcinoma	1	0	1
PANCREAS			2	1	1
	carcinoma	Breat - Invasive Ductal Carcinoma	1	0	1
Adend	carcinoma	Prostate - Adenocarcinoma	1	1	0
NASOPHARY	NΧ		4	3	1
•	nous Cell Carcinoma	Thyroid - Papillary Adenocarcinoma	1	1	0
•	nous Cell Carcinoma	Hypopharynx - Sq Cell Ca	1	0	1
•	nous Cell Carcinoma	Rectum - Mucinous Adenocarcinoma	1	1	0
Squan	nous Cell Carcinoma	Thyroid - Papillary Adenocarcinoma	1	1	0
LUNG			5	2	3
	ocarcinoma ocarcinoma	Breast - Invasive Ductal Carcinoma	1 1	0	1 1
	oid Tumor	Large B-Cell Lymphoma Colon - Adenocarcinoma	1	0	0
	nous Cell Carcinoma	Skin - Sebaceous Adenocarcinoma	1	0	1
Small	Cell Carcinoma	Prostate - Adenocarcinoma	1	1	0
BONE			3	1	2
	sarcoma	Eye Retinoblastoma	1	0	1
	sarcoma	Bone Marrow - AML Thyroid - Papillary Adenocarcinoma	1	1	0
	oid Cystic Carcinoma	Thyrold - Fabiliary Adenocarcinonia	'		'
BONE MARRO		Musicanaliforativa Disorder	15	11	4
	Myeloid Leukemia Myeloid Leukemia	Myeloproliferative Disorder Thyroid - Papillary Adenocarcinoma	1	1 1	0
	Myeloid Leukemia	Bone Marrow - Polycythemia Vera	1	0	1
	Myeloid Leukemia	Liver - Hepatoblastoma	1	1	0
	Myeloid Leukemia	Bone Marrow - Multiple Myeloma	1	1	0
	Myeloid Leukemia Myeloid Leukemia	Myelodysplastic Syndrome Bone - Myeloid Sarcoma	1	1 1	0
	Myeloid Leukemia	Thoracic - Sarcoma	1	1	0
	Myeloid Leukemia	Thyroid - Papillary Adenocarcinoma	1	1	0
B-cell Leuke		Liver - Hepatocellular Carcinoma Brain - Choroid Plexus Carcinoma	1	1 0	0 1
	leukemia	B-cell Lymphoblastic Leukemia	1	1	0
Hairy (Cell Leukemia	Breast - Invasive Ductal Carcinoma	1	0	1
	ic Myeloid Leukemia ic Myeloid Leukemia	Breast - Invasive Ductal Carcinoma Bone - Myeloid Sarcoma	1	0	1 0
	•	20110 Injuidid Garooma			J
SOFT TISSUE	nous Cell Carcinoma	Bone Marrow - CML	2 1	1	1
•	d Chondrosarcoma	Thyroid - Papillary Adenocarcinoma	1	0 1	0
,		. ,			

PRIM <i>F</i>	RY SITE H	ISTOLOGY		OTHER PRIMARIES	ALL		
		- Not Otherwise Spe	cified)	(PREVIOUS OR CONCURRENT)		MALE	FEMALE
	,		,	,			
SKIN					9	4	5
Ortart	Basal Cell Ca N	lodular	Skin	Hip - Basal Cell Ca	1	1	0
	Basal Cell Ca N			- Basal Cell Ca Nodular	1	0	1
	Basar Con Ca II	loadiai		d - Basal Cell Ca		J	•
	Basal Cell Ca N	lodular	-	nant Lymphoma	1	1	0
	Basal Cell Carc			- Basal Cell Ca	1	0	1
	Basal Cell Carc			pharynx - Sq Cell Ca	1	0	1
	Basal Adenocal			n - Mucinous Adenocarcinoma	1	1	0
	Basal Adenocal			- Malignant Melanoma	1	0	1
	Dermatofibrosa			_	1	1	1
			-	oid - Papillary Adenocarcinoma	1		0
	Sebaceous Ade	enocarcinoma	Lung	- Sq Cell Ca	1	0	1
DDEAG	eT.				20	^	22
BREAS		Carainama	Clair	Donal Call Ca	32	0	32
	Invasive Ductal			- Basal Cell Ca	1	0	1
	Granular Cell T			pharynx - Undifferentiated Ca	1	0	1
	Intraductal Card		•	oid - Papillary Adenocarcinoma	1	0	1
	Invasive Ductal			r Breast - Invasive Ductal Ca	1	0	1
	Invasive Ductal			r Breast - Invasive Ductal Ca	1	0	1
	Lobular Carcino			lar Ca In Situ	1	0	1
	Invasive Ductal			r Breast - Invasive Ductal Ca	1	0	1
	Intraductal Card		DCIS		1	0	1
	Invasive Ductal			oid - Papillary Adenocarcinoma	1	0	1
	Invasive Ductal		-	oid - Papillary Adenocarcinoma	1	0	1
	Invasive Ductal			y - Serous Cystadenoma	1	0	1
	Invasive Ductal			r Breast - Invasive Ductal Ca	1	0	1
	Invasive Ductal			r Breast - Lobular Ca	1	0	1
	Spindle Cell Ca		Sarco		1	0	1
	Invasive Ductal		-	oid - Papillary Microcarcinoma	1	0	1
	Invasive Ductal			- Hepatocellular Carcinoma	1	0	1
	Invasive Ductal			kin's Lymphoma	1	0	1
	Invasive Ductal			tine - Adenocarcinoma	1	0	1
	Papillary Microc			x Uteri - Sq Intraepithelial Neoplas		0	1
	Invasive Ductal			metrium - Endometrioid AdenoCa	1	0	1
	Invasive Ductal	Carcinoma	-	oid - Follicular Carcinoma	1	0	1
	Carcinoma			ey - Renal Cell Ca	1	0	1
	Carcinoma		Othe	r Breast - Carcinoma	1	0	1
	Invasive Ductal	Carcinoma	Rectu	um - Adenocarcinoma	1	0	1
			Thyro	oid - Papillary Adenocarcinoma			
	Lobular Carcino	oma	Othe	r Breast - Lobular Carcinoma	1	0	1
	Invasive Ductal	Carcinoma	Thyro	oid - Papillary Adenocarcinoma	1	0	1
	Invasive Ductal	Carcinoma	Othe	r Breast - Invasive Ductal Ca	1	0	1
	Invasive Ductal	Carcinoma	Othe	r Breast - Invasive Ductal Ca	1	0	1
	Invasive Ductal	Carcinoma	Thyro	oid - Papillary Adenocarcinoma	1	0	1
	Invasive Ductal	Carcinoma	-	st - Papillary Carcinoma	1	0	1
	Invasive Ductal			r Breast - Invasive Ductal Ca	1	0	1
	Lobular Carcino			r Breast - Lobular Carcinoma	1	0	1

PRIMARY SITE	HISTOLOGY	OTHER PRIMARIES	ALL		
2016	(NOS - Not Otherwise Spe			MALE	FEMALE
CORPUS UTERI			5	0	5
Adenoca		Breast - Invasive Ductal Ca	1	0	1
Adenoca Adenoca		Breast - Invasive Ductal Ca Colon - Adenocarcinoma	1	0	1
	trioid Adenocarcinoma	Breast - Invasive Ductal Ca	1	0	1
Stromal S		Breast - Carcinoma	1	0	1
	5 a. 5 a. 1 a.	2.0001			·
OVARY			3	0	3
	Cystadenocarcinoma	Breast - Invasive Ductal Ca	1	0	1
	s Adenocarcinoma at Serous Tumor	Breast - Invasive Ductal Ca Othre Ovary - Malignant Serous Tumo	1	0	1
ivialignan	it Serous Turnor	Office Ovary - Malignant Serous Turno	'	U	
PROSTATE GLA	ND		5	5	0
Adenoca		Glottis - Sq Cell Carcinoma	1	1	0
Adenoca	rcinoma	Rectum - Adenocarcinoma	1	1	0
		Colon - Adenocarcinoma			
Adenoca		Liver - Hepatocellularcarinoma	1	1	0
Adenoca		Colon - Adenocarcinoma	1	1	0
Adenoca	rcinoma	Liver - Hepatocellularcarinoma	1	1	0
KIDNEY			6	3	3
	ell Carcinoma	Non-Hodgkin's Lymphoma	1	1	0
	II Sarcoma	Breast - Invasive Ductal Ca	1	0	1
	II Adenocarcinoma	Chromophobe Renal Cell Ca	1	1	0
	ell Carcinoma ell Adenocarcinoma	Neuroectodermal Tumor Female Genital - Placenta Malignancy	1 1	0	1 1
	ell Carcinoma	Non-Hodgkin's Lymphoma	1	1	0
rteriai oc	on Carcinoma	Non-Hougkin's Lymphoma	'	•	J
URINARY BLADI	DER		3	3	0
Invasive	Micropapillary Ca	Bladder-Non-Inv Papillary Trans. Cell (1	1	0
	Trans. Cell Ca	Kidney - Clear Cell Ca	1	1	0
Carcinon	na	Lung - Sq Cell Ca	1	1	0
THYROID			27	11	16
	Adenocarcinoma	Esophagus - Adenocarcinoma	1	1	0
	Microcarcinoma	Cervix - Sq Cell Ca	1	0	1
	Carcinoma	Pancreas- Neuroendocrine Carcinoma		0	1
	Carcinoma	Ovary - Endometrioid Adenocarcinoma		0	1
	Carcinoma	Liver - Hepatocellular Ca	1	1	0
Papillary	Carcinoma	Maxillary Sinus - Neuroectodermal Tun	1	1	0
	y Carcinoma	Breast - Invasive Ductal Ca	1	0	1
	Carcinoma	T-Cell Lymphoblastic Lymphoma	1	0	1
	Carcinoma	Ovary - Micropapillary Serous Ca	1	0	1
	Carcinoma	Kidney - Renal Cell Ca	1	1	0
	r Carcinoma r Carcinoma	Anal Canal - Sq Cell Ca Breast - Invasive Ductal Ca	1	0 0	1
	Microcarcinoma	Glottis - Sq Cell Ca	1	1	0
	Adenocarcinoma	Rectum - Adenocarcinoma	1	0	1
		Breast - Invasive Ductal Ca	·		·
Papillary	Adenocarcinoma	Brain - Malignant Lymphoma	1	0	1
	Adenocarcinoma	Adrenal Gland - Cortical Carcinoma	1	1	0
Papillary	Adenocarcinoma	Large B-Cell Lymphoma	1	0	1
	Carcinoma	Langerhans Cell Histocytosis	1	1	0
	Adenocarcinoma	Leukemia	1	0	1
	Carcinoma	Bone Marrow- AML	1	1	0
	Adenocarcinoma	Breast - Invasive Ductal Ca	1	0	1
	Adenocarcinoma	Oral Cavity - Mucoepidermoid Ca	1	0	1
	Adenocarcinoma	Pancreas- Neuroendocrine Carcinoma	1	0	1
	Adenocarcinoma Adenocarcinoma	Soft Tissue - Myxoid Chondrosarcoma Stomach - Diffuse Carcinoma	1	1 1	0
	Adenocarcinoma	Larynx - Sq Cell Ca	1	1	0
	Adenocarcinoma	Breast - Invasive Ductal Ca	1	0	1
		'			

PRIMARY SITE	HISTOLOGY		OTHER PRIMARIES	ALL		
2016	(NOS - Not Otherwise Sp	ecified)	(PREVIOUS OR CONCURRENT)	CASES	MALE	FEMALE
						_
BRAIN, CNS		_		6	3	3
Atypical I	Meningioma		t - Invasive Ductal Ca	1	0	1
0" 1		-	oid - Follicular Carcinoma		0	
Glioma M		_	B- Cell Lymphoma	1	0	1
Glioblasto			Ependymoma	1	1	0
•	Astrocytoma		- Glioma Malignant	1	1	0
Meningio	ma	-	id - Papillary Adenocarcinoma	1	0	1
Oli III.		_	- Adenocarcinoma			_
Glioblasto	oma	Brain	- Oligodendroglioma	1	1	0
HODGKIN'S DISE	ASE			2	2	0
Hodgkin's	Lymphoma	Hodgl	kin's Lymphoma	1	1	0
_	Lymphoma		Lymphocytic Lymphoma	1	1	0
_						
NON-HODGKIN'S	LYMPHOMA			10	4	6
Diffuse La	arge B-Cell Lymphoma	Liver -	Hepatocellular Ca	1	0	1
Non-Hodg	gkin's Lymphoma	Mouth	n - Non-Hodgkin's Lymphoma	1	0	1
	Lymphoma	Kidne	y - Renal Cell Carcinoma	1	1	0
Marginal	B-Cell Lymphoma	Breas	t - Invasive Ductal Carcinoma	1	0	1
_	Cell Lymphoma	Hodgl	kin's Lymphoma	1	0	1
	gkin's Lymphoma		y - Renal Cell Carcinoma	1	1	0
-	gkin's Lymphoma	-	id - Papillary Adenocarcinoma	1	0	1
-	Cell Lymphoma		y - Renal Cell Carcinoma	1	1	0
_	Cell Lymphoma	-	id - Papillary Adenocarcinoma	1	0	1
Non-Hodg	gkin's Lymphoma	Liver -	Hepatocellular Ca	1	1	0
MAYELOMA				2	2	4
MYELOMA	Avalomo	Clair	Matura T Call Lymphama	3	2	
Multiple N Multiple N			Mature T-Cell Lymphoma	1	1 1	0
Multiple N	•	-	id - Large B-Cell Lymphoma nacytoma	1	0	1
Multiple N	луеюна	Flasii	lacytoma		U	,
OTHER MALE GE	NITAL			2	2	0
Squamou	s Cell Carcinoma	Hodgl	kin's Lymphoma	1	1	0
Sarcoma		Follic	ular Lymphoma	1	1	0
OTHER HEMATOI	POIETIC			1	1	0
	plastic Syndrome	Hodak	kin's Lymphoma	1	1	0
	•	9.	7 1		_	
OTHER ENDOCRI		-	id Danillan Adan	1	1	0
Adrenal C	Cortical Carcinoma	inyro	id - Papillary Adenocarcinoma	1	1	0
UNKNOWN PRIM	MARY			2	1	1
Basosqu	amous Carcinoma	Glotti	s - Sq Cell Ca	1	1	0
=	Neuroectodermal Ca	Kidne	y - Renal Cell Ca	1	0	1

STAGE OF DISEASE AT DIAGNOSIS

Stage in any malignant process may be defined as the particular step, phase, or extent in a tumor's development, which is one of the predictors for outcome and treatment selection assigned at the time of initial diagnosis. The microscopic appearance, extent, and biological behavior of a tumor, as well as host factors, play a part in prognosis and are therefore important in staging.

The SEER (Surveillance, Epidemiology and End Results) Summary Staging Guide was utilized for all stageable cases. This system summarizes the disease categories into four general staging groups (i.e., in situ, localized, regional and distant). Stage categories are based on a combination of clinical observations and operative-pathological evaluation.

Summary Staging Definitions:

IN SITU: Intraepithelial, noninvasive, noninfiltrating

LOCALIZED: Within organ

a. Invasive cancer confined to the organ of origin

b. Intraluminal extension where specified

REGIONAL: Beyond the organ of origin

a. By direct extension to adjacent organs/tissues

b. To regional lymph nodes

c. Both (a) and (b)

DISTANT: Direct extension or metastasis

a. Direct continuity to organs other than above

b. Discontinuous metastasis

c. To distant lymph nodes

Systemic diseases, i.e., leukemia and multiple myeloma and cases of unstageable unknown primary were disregarded in graphically illustrating the stages for all analytic cases seen at KFSH&RC in 2016 (Figure 13).

In addition to the SEER Summary Staging, the cases were also staged according to the American Joint Committee on Cancer (AJCC) TNM system. This scheme is based on the premise that cancers of similar histology or site of origin share similar patterns of growth and extension. This system is based on the assessment of three components:

T: Extent of the primary tumor


N: Absence or presence and extent of regional lymph node involvement

M: Absence or presence of distant metastasis

Analytic cases of five major sites, i.e., breast, Non-Hodgkin's lymphoma, Nasopharynx, Thyroid, Hodgkin's lymphoma and Liver are presented in Table 12 with their clinical group stages and yearly comparative figures from 2011 to 2016.

FIGURE 13

DISTRIBUTION OF ANALYTIC CASES BY (SEER) STAGE AT DIAGNOSIS 2016 (TOTAL CASES=3000)



REGIONAL 911 (30.4%)

^{*}Excludes Hematopoietic Primaries (234 cases)

^{**}Excludes Unstageable Unknown Primaries (49 cases)

TABLE 12

AJCC CLINICAL TNM STAGE GROUP OF 2011-2016 CASES OF MAJOR SITES *BY YEAR 2011-2016

			BREA	NST			
STAGE	2011	2012	2013	2014	2015	2016	TOTAL
0	12	14	13	8	6	4	57
0A	0	0	0	0	0	2	2
OIS	0	0	0	0	1	1	2
1	0	0	7	12	3	11	33
1A	39	37	27	14	19	11	147
1B	0	0	2	0	0	1	3
2	0	0	1	1	0	1	3
2A	67	72	84	50	41	29	343
2B	61	34	61	62	51	23	292
3	0	0	0	1	1	2	4
3A	30	31	47	43	50	18	219
3B	46	39	50	48	37	11	231
3C	3	8	2	9	10	6	38
4	70	71	70	52	66	21	350
4B	0	0	0	1	1	1	3
UNSTAGEABLE	0	0	1	0	0	0	1
UNK	82	66	66	30	24	8	276
TOTAL	410	372	431	331	310	150	2004

			ſ	NHL			
STAGE	2011	2012	2013	2014	2015	2016	TOTAL
1	1	4	6	5	2	1	19
1A	22	27	17	11	11	1	89
1B	1	3	7	7	9	1	28
2	0	3	2	3	2	1	11
2A	15	16	14	17	15	1	78
2B	9	5	10	5	10	0	39
3	3	5	2	8	6	1	25
3A	9	10	13	4	11	1	48
3B	6	9	16	5	7	0	43
3C	0	0	0	0	1	0	1
4	5	8	5	12	15	3	48
4A	26	24	17	11	14	0	92
4B	31	31	46	30	25	4	167
UNSTAGEABLE	1	2	1	1	5	0	10
UNK	10	6	3	6	5	26	56
TOTAL	139	153	159	125	138	40	754

			THYROII	D			
STAGE	2011	2012	2013	2014	2015	2016	TOTAL
1	158	167	166	64	84	37	676
1A	0	0	0	0	0	1	1
2	11	12	15	8	16	9	71
3	12	12	8	8	11	11	62
4	1	2	0	4	3	1	11
4A	1	1	6	0	4	1	13
4B	1	0	0	0	0	2	3
4C	17	3	8	0	8	0	36
UNSTAGEABLE	0	1	0	0	1	0	2
UNK	44	48	40	19	48	17	216
TOTAL	245	246	243	103	175	79	1091

		Н	ODGKINS DI	SEASE			
STAGE	2011	2012	2013	2014	2015	2016	TOTAL
1	0	1	0	1	1	0	3
1A	4	9	8	14	10	0	45
1B	0	0	1	1	0	0	2
2	0	1	0	3	1	1	6
2A	21	24	17	27	26	0	115
2B	10	13	13	17	7	1	61
3	0	0	3	6	3	1	13
3A	13	17	14	17	12	0	73
3B	17	11	17	13	7	5	70
4	0	1	5	5	10	1	22
4A	6	11	3	3	5	0	28
4B	24	28	25	34	19	1	131
88	0	0	0	0	0	2	2
99	1	1	1	0	2	22	27
TOTAL	96	117	107	141	103	34	598

LIVER								
STAGE	2011	2012	2013	2014	2015	2016	TOTAL	
1	20	25	18	2	16	9	90	
2	16	11	10	6	4	1	48	
2B	0	0	0	0	0	1	1	
3	0	0	0	0	1	0	1	
3A	7	3	6	2	2	2	22	
3B	2	1	2	1	4	1	11	
3C	0	2	0	0	0	1	3	
4	2	4	0	4	5	4	19	
4A	3	1	0	0	1	3	8	
4B	15	6	10	2	5	1	39	
88	13	7	13	3	3	0	39	
99	32	41	39	5	7	1	125	
TOTAL	110	101	98	25	48	24	406	

IV. With permission from Saudi Cancer Registry (SCR) Annual Report, 2016:

Cancer incidence in Saudi Arabia, 2016.

Between January 01 and December 31, 2016, the total number of newly diagnosed cancer cases reported to the Saudi Cancer Registry (SCR) was 17,602. Overall cancer was more among women than men; it affected 8,044 (45.7%) males and 9,558 (54.3%) females. Total of 13,562 cases were reported among Saudi nationals, 3,834 among non-Saudi, and 206 of unknown nationality.


Total of 16,859 cases were analyzed, of which 13,161 (78.1%) were Saudi nationals and 3,698 (21.9%) were Non-Saudi.

Among Saudis 5,803 (44.1%) were males and 7,358 (55.9%) were females with a male to female ratio of 100 to 126. The crude incidence rates (CIR) of all cancers were 56.6/100,000 in males and 74.5 / 100,000 in females.


The overall age-standardized incidence rate (ASR) was 74.7/100,000 in males and 91.3/100,000 in females.

Eastern region reported the highest ASR among males and females (104.3/100,000 and 131.3 /100,000 for males and females respectively), whereas, Jazan region reported the lowest ASR among males and females (33.7/100,000 and 40.6/100,000 for males and females respectively)

Most common Cancers among Saudi Nationals in 2016 of all ages



Age Standardizes Rate (ASR of all cancer sites among Saudi nationals, 2016



V. APPENDIX

REQUESTS FOR TUMOR REGISTRY DATA 2016

February

Dr. M. Alshabanah Year (1990-2016) Cardiac Sarcoma patients including grate vessels. Patients MRN, year of diagnosis, Tumor size, site, histology and grade. If patient underwent, Surgery, Chemo, Cycle and Radiation. Last date of follow up Dr. M. Abomelha Testis malignant cases by histology by year 1975-2013. SEER summary stage of testis malignant cases by year 1975-2013. Total cases data of nationality, age, region 1975-2013. Pediatric testis malignant cases by histology by year 1975-2013. Dr. S. Akhtar Diffuse large B cell lymphoma/NHL-NOS with Gastric involvement. Gastric DLBLL May MRN's of patients with metastatic Renal Cell Carcinoma from 2007-2014 Dr. S. Bazarbashi June All patients diagnosed with Gastric Cancer and GES from 2009-2013 Dr. N. Agha including all stages. Oct Dr. A. Hanbali Acute Promyelocytic Leukemia 1975-2014 Total #, MRN. Gender and Histology Breast Cancer Statistic, Pathology, Number of cases 5 years. Dr. A. Alsayed Staging male regions in Kingdom. Number of Lymphoma patients from 1975-date. Dr. S. Akhtar Total number of cancer patient's same year. Breakdown of lymphoma patients according to diagnosis NHL-VS HL Sex, Age, (>60+<60) Hodgkin lymphoma and baseline variables for registry data. Dr. M. Rauf Nov For Database of Sarcoma 1997-2016 Ewing Sarcoma 14 years and above Dr. Memon MRN of Giant cell tumors from 2002-2016 Dr. M. Elshenawy Dec Epithelial Ovarian cancer. Age: 50 years old or less from 2008-2016 Dr. H. Alhusaini

Dr. A. Alsuhaibani

All patient's population diagnosed as Desmoids Tumor or Fibromatosis in

KFSHRC from 2001-2016

VI. GLOSSARY OF TERMS

Accessioned: Cases are entered into the Tumor Registry by the year in which they were first seen at KFSH&RC for each primary cancer.

Age of Patient: Recorded in completed years at the time of diagnosis.

Analytic Cases: Cases which were first diagnosed and/or received all or part of their first course of treatment at KFSH&RC.

Non-Analytic Cases: Cases diagnosed elsewhere and received all of their first course of treatment elsewhere.

Case: A diagnosis or finished abstract. A patient who has more than one primary is reported as multiple cases.

Crude Relative Frequency: The proportion of a given cancer in relation to all cases in a clinical or pathological series.

First Course of Treatment: The initial tumor-directed treatment or series of treatments, usually initiated within four months after diagnosis.

Stage of Disease: Extent of disease process determined at first course of treatment.

SEER (Surveillance, Epidemiology and End Results) Summary Staging:

In Situ: Tumor meets all microscopic criteria for malignancy except invasion.

Local: Tumor is confined to organ of origin.

Regional: Tumor has spread by direct extension to immediately adjacent organs and/or lymph nodes and appears to have spread no further.

Distant: Tumor has spread beyond immediately adjacent organs or tissues by direct extension and/or has either developed secondary or metastatic tumors, metastasized to distant lymph nodes or has been determined to be systemic in origin.

AJCC (American Joint Committee on Cancer) TNM Staging: A classification scheme based on the premise that cancers of similar histology or site or origin share similar patterns of growth and extension.

T+N+M = Stage

T: Extent of primary tumor

N: Extent of regional lymph node involvement

M: Distant Metastasis

Clinical Stage: Classification based on the evidence acquired before treatment. Such evidence arises from physical examination, imaging, endoscopy, biopsy, surgical exploration and other relevant findings.

Pathologic Stage: Classification based on the evidence acquired before treatment, supplemented or modified by the additional evidence acquired from surgery and from pathologic examination of the resected specimen.